LDN Q&A: Your Questions Answered A Supportive Guide for the LDN Support Group Download your free LDN Primer Booklet from www.LDNSupportGroup.org January 18 2026 Important Disclaimer This guide shares information based on published research and community experiences. It is not medical advice. LDN is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Always consult your doctor before starting, adjusting, or stopping any medication. Part 1: Quick FAQ These are the most common questions we see in our community. For deeper explanations, see the comprehensive guide in Part 2. Q1: Should I take LDN in the morning or at night? There's no universal "right" answer. Nighttime is traditionally recommended, but if you experience insomnia, morning dosing may work better for you. Some people feel drowsy taking it in the morning initially, but this often improves. Try what feels right and give any change at least 1-2 weeks. Q2: I'm having terrible insomnia on LDN. What should I do? Insomnia is one of the most common side effects, especially at night. Options include: switching to morning dosing, reducing your dose, or if you just started, giving it 1-2 weeks to see if it improves. If insomnia persists despite these adjustments, discuss with your prescriber. Q3: Should I push through side effects or reduce my dose? It depends on severity. Mild effects (slight sleep changes, vivid dreams) often resolve in 1-2 weeks. Moderate to severe effects (significant insomnia, bad headaches, vertigo, irritability) are signals to reduce your dose. If symptoms are getting worse rather than better, back off. Q4: I tolerated LDN fine at first, but now I'm getting worse the longer I take it. Why? This pattern happens to some people. LDN's effects can be cumulative, and what your body tolerated initially may become too much over time. Your underlying condition may also have changed. If you've tried reducing doses and breaks without success, discuss with your provider whether to stop. Q5: How slowly should I increase my dose? Standard protocols suggest reaching 4.5 mg in 2-4 weeks, but this is too fast for many people. If you're sensitive or severely ill, consider 2-4 week intervals between increases—or even longer. Some very sensitive patients need months between dose changes. Patience is key. Q6: What's the lowest dose I can try? Clinical protocols recognize ultra-low doses in the microgram range (1-2 mcg), very-low doses (0.01-0.5 mg), and traditional low doses (1-4.5 mg). If you're highly sensitive, starting at 0.5 mg or lower and titrating very slowly may help. Discuss options with your prescriber. Q7: Does it matter which compounding pharmacy I use? Some people report differences between pharmacies. If you're sensitive, you might try a formulation without silica or other common fillers. There isn't definitive research on this, but some individuals with MCAS or sensitivities notice improvements with cleaner formulations. Q8: Is it normal to feel worse before feeling better? Some people experience a brief adjustment period with mild side effects that resolve. However, feeling significantly worse that doesn't improve over 2-4 weeks isn't necessarily "normal"—it may mean the dose is too high for you. Listen to your body. Q9: What if LDN just doesn't work for me? Research suggests about one-third of people don't respond to standard LDN therapy. This isn't a personal failure—it may mean your condition works through different pathways, or your endorphin reserves are depleted. Some people try again successfully later after addressing other health factors. Q10: I have POTS, hEDS, or MCAS. Any special considerations? These complex conditions often require extra care. Start at very low doses and titrate extremely slowly. For MCAS, LDN alone may not be sufficient—complementary treatments like mast cell stabilizers are sometimes added. Work closely with a provider experienced in these conditions. Part 2: Comprehensive Guide This section provides in-depth information based on clinical experience and published research. Remember, everyone's journey with LDN is unique. Understanding How People Respond to LDN One of the most important things to understand is that not everyone responds to LDN in the same way. Clinical experience and research suggest that people generally fall into three categories: Category 1: LDN Works Well on Its Own For some people, LDN alone produces meaningful and sustained improvement. These individuals typically have adequate baseline endorphin reserves, moderate symptom severity, and good overall functional capacity. Research in fibromyalgia has shown response rates around 57-65%, with some studies demonstrating significant pain reduction compared to placebo (Younger et al., 2013; Toljan & Vrooman, 2023). Category 2: LDN Helps, But Isn't Enough Alone In more complex situations, LDN plays an important supporting role but may not achieve the full results someone is hoping for on its own. Conditions that often fall into this category include mast cell activation syndrome (MCAS), Long COVID, chronic inflammatory response syndrome (CIRS), and complex regional pain syndrome. In these cases, LDN may calm the immune system enough to make other treatments more effective and better tolerated (Kim, 2025). Category 3: Non-Responders Some people simply don't respond to LDN at any dose. This may relate to severely depleted endorphin reserves, genetic variations in opioid receptor function, or conditions that aren't primarily mediated by the pathways LDN affects. If you've given LDN a thorough trial without benefit, this doesn't mean you've failed—it may simply mean LDN isn't the right tool for your particular situation. The Endorphin Reserve Concept A key concept in understanding LDN therapy is what clinicians call "endorphin reserve." LDN works partly by temporarily blocking opioid receptors, which triggers your body to produce more endorphins. But if your body's endorphin-producing capacity is already depleted from prolonged illness, this mechanism may not work as expected. Healthcare providers experienced with LDN often assess functional capacity to estimate endorphin reserve. They may ask about duration of illness, sleep quality, energy levels, recovery time from setbacks, and ability to perform daily activities. People with very low functional capacity often need a much gentler approach to starting LDN (Kim, 2025). Dosing Strategies: One Size Does NOT Fit All This is perhaps the most important section for our community members who are struggling with side effects. Standard Dosing The commonly cited protocol of starting at 1.5 mg and working up to 4.5 mg over 2-4 weeks works well for people with moderate illness and good functional capacity. However, many people in health support communities like ours have more complex situations that require a different approach. Low and Ultra-Low Dosing The LDN Research Trust recognizes three dosing categories: ultra-low dose (microgram range, 1-2 mcg), very-low dose (0.01-0.5 mg daily), and the traditional low dose (1-4.5 mg, sometimes up to 10 mg). At very low doses, naltrexone may work through different mechanisms, potentially acting more gently on the system through a phenomenon called hormesis (LDN Research Trust, 2024). For people who are severely ill, have low functional capacity, or are highly sensitive, starting at 0.5 mg or even lower and increasing very slowly may be essential. Some sensitive individuals may need 2-4 weeks between dose increases, while the most sensitive may need 1-3 months between adjustments. This is a marathon, not a sprint. When Side Effects Persist at Low Doses If you're experiencing persistent side effects even at very low doses, this may indicate that your endorphin reserves are significantly depleted. Options include dropping to an even lower dose, extending the time between dose increases, or discussing with your healthcare provider whether LDN is appropriate for your current situation. Sometimes stepping away and addressing other aspects of health first allows people to try LDN again successfully later. Morning vs. Night: Finding What Works for You The timing question comes up constantly in our group, and for good reason—it can make a significant difference in tolerability. Nighttime dosing is traditionally recommended because LDN's brief opioid receptor blockade coincides with the body's natural endorphin release during sleep. Many people do well with this approach. However, insomnia and vivid dreams are among the most commonly reported side effects, and taking LDN at night can make these worse for some people. Morning dosing works better for those who experience sleep disruption. Some people report feeling drowsy or "out of it" when first switching to morning dosing, but this often improves as the body adjusts. There's no definitive research saying one time is universally better—it's about finding what works for your body. If nighttime dosing is causing severe insomnia, switching to morning is absolutely worth trying. Give any timing change at least a week or two before deciding if it's working. Common Side Effects and What They May Mean Side Effect What It May Indicate Suggested Approach Insomnia / vivid dreams Common with nighttime dosing Try morning dosing; may improve with time Headaches Adjustment period or dose too high Often resolves in 1-2 weeks; reduce dose if severe Fatigue / drowsiness Body adjusting; may indicate dose sensitivity Consider timing change; reduce dose if persistent Irritability / mood changes Possible dose sensitivity Reduce dose; ensure adequate rest Nausea / GI upset Common early effect Take with food; usually improves Vertigo / dizziness May indicate dose too high Reduce dose; titrate more slowly Increased pain (temporary) Some experience initial flare May resolve; discuss with provider if persists Most side effects are temporary and resolve within the first few weeks. However, if side effects persist or worsen despite dose adjustments, this is important information to share with your healthcare provider. When You Initially Tolerated LDN But Now Can't This is a pattern we see repeatedly in our community, and it can be deeply frustrating. You started LDN without problems, built up to a certain dose, and then symptoms appeared that get worse the longer you stay on it—even when you drop back down. Several things may explain this pattern. First, LDN's effects are cumulative over time, so what your body tolerated at first may become too much as levels build. Second, your underlying condition may have changed, affecting how you respond to LDN. Third, there may be interactions with other factors in your health that weren't present initially. If you've tried reducing the dose, taking breaks, and using the every-other-day method without success, it may be time to have a candid conversation with your prescriber about whether to discontinue—at least for now. Stopping LDN is not a failure. Some people return to it successfully later when other aspects of their health have been addressed. Should I Power Through Side Effects or Reduce My Dose? This is one of the most common questions we receive, and the answer depends on the severity and type of side effects. Mild, tolerable side effects (slight sleep changes, mild headache, vivid but not disturbing dreams) often resolve within 1-2 weeks as your body adjusts. If the side effects aren't significantly impacting your quality of life, it may be reasonable to stay at your current dose and give it more time. Moderate to severe side effects (significant insomnia, severe headaches, marked irritability, vertigo, blurred vision) are signals from your body that the current dose is too much. In these cases, reducing the dose or pausing is generally the wiser choice. There's no benefit to "pushing through" if it means feeling miserable. A practical approach: if side effects are getting progressively worse rather than improving, back off. If they're stable or slowly improving, you might give it more time. Special Considerations for POTS, hEDS, and MCAS Many members of our community are managing complex overlapping conditions like postural orthostatic tachycardia syndrome (POTS), hypermobile Ehlers-Danlos syndrome (hEDS), and mast cell activation syndrome (MCAS). These conditions often require extra care when starting LDN. For MCAS in particular, LDN may be helpful but often isn't sufficient on its own. Clinical protocols sometimes combine LDN with mast cell stabilizers like ketotifen or cromolyn sodium (Weinstock et al., 2018). If you have MCAS and are struggling with LDN tolerance, discussing these complementary approaches with your healthcare provider may be worthwhile. People with these conditions often benefit from starting at the lowest possible doses and titrating extremely slowly—sometimes over many months rather than weeks. Does the Compounding Formulation Matter? Some community members report significant differences in how they tolerate LDN from different compounding pharmacies or with different inactive ingredients (excipients). While there isn't robust research on this topic, clinical experience suggests that some people are sensitive to fillers like silica, certain dyes, or other additives. If you're highly sensitive or have MCAS, working with a compounding pharmacy that can prepare LDN with minimal excipients may be worth exploring. Common requests include formulations without silica, dye-free preparations, and hypoallergenic fillers. When to Consider Stopping LDN LDN isn't right for everyone, and recognizing when it's not working is just as important as giving it a fair trial. Consider discussing discontinuation with your healthcare provider if: side effects persist despite multiple dose adjustments and timing changes, you've tried for several months without any perceived benefit, side effects significantly outweigh any benefits, or your symptoms are progressively worsening on the medication. Stopping LDN is generally straightforward since it doesn't cause physical dependence. Some people notice temporary changes when stopping, but these typically resolve within a few days. A Final Word of Support Managing chronic health conditions is challenging, and trying to optimize LDN therapy can feel like solving a puzzle with many pieces. Please remember that your experience is valid, even if it doesn't match what others describe. What works beautifully for one person may not work for another, and that's okay. Always work with a healthcare provider who understands LDN and can help guide your decisions. This community is here to share experiences and support each other, but personalized medical guidance is essential. Be patient with yourself. Be willing to adjust. And know that whether LDN ends up being part of your health toolkit or not, you're on a path toward understanding your body better. LDN Support Group About the Author: Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in using LDN (Low Dose Naltrexone) to treat autoimmune conditions, chronic pain, integrative oncology, and complex conditions, including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com This document is for educational purposes only and does not constitute medical advice. Individual results vary. Please consult your healthcare provider for personalized guidance. References Bruun, K. D., Christensen, R., Amris, K., et al. (2021). Low-dose naltrexone for the treatment of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial. Trials, 22(1), 804. https://doi.org/10.1186/s13063-021-05804-6 Kim, Y. H. (2018). Ultra low dose naltrexone, micro dosing [Conference presentation]. LDN Research Trust 2018 Conference. Kim, Y. H. (2025). Low-dose naltrexone primer: A clinical guide to optimizing LDN therapy. Direct Integrative Care. https://www.directintegrativecare.com LDN Research Trust. (2024). Dosing information for prescribers. https://ldnresearchtrust.org Toljan, K., & Vrooman, B. (2023). Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions. Biomedicines, 11(4), 1087. https://doi.org/10.3390/biomedicines11041087 Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, bcr2017221405. https://doi.org/10.1136/bcr-2017-221405 Yang, J., Shin, K. M., Do, A., et al. (2023). The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: A systematic review. Journal of Pain Research, 16, 1017-1023. https://doi.org/10.2147/JPR.S397456 Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial. Arthritis & Rheumatism, 65(2), 529-538. https://doi.org/10.1002/art.37734 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451-459. https://doi.org/10.1007/s10067-014-2517-2

An Evidence-Graded Review of Over-the-Counter Botanicals and the Two FDA-Approved Prescription Options Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and it is not a substitute for individualized care. Supplements and prescription medications carry real risks and interactions. Do not start, stop, or change any therapy without consulting a qualified healthcare provider who knows your full history. The honest headline first: for the great majority of over-the-counter libido products marketed to women, the evidence that they outperform a placebo is thin, inconsistent, or absent. Most have never been tested in a rigorous randomized trial, and where trials exist they are usually small, short, and industry-funded. A handful of ingredients do show a real—though modest—signal. And the two prescription medications approved for low desire have the strongest data of anything in this space, yet still deliver effect sizes most clinicians would call small. None of that means "nothing works." It means the useful question is rarely which bottle—it is why has desire changed, and what is actually driving it. This review walks through that reasoning first, then grades the ingredients one by one against what the published literature does and does not support. Start With the Differential, Not the Supplement Aisle Low sexual desire is a symptom, not a diagnosis. Before any botanical is worth considering, the more productive step is to look for a treatable driver. In clinical practice these cluster into five buckets: Hormonal shifts — perimenopause and menopause, low testosterone, the postpartum period, thyroid dysfunction, PCOS, and hormonal contraception (which lowers free testosterone in some women). Medications — SSRIs and SNRIs are the classic culprits; some antihypertensives, antipsychotics, and hormonal agents also blunt desire. Medical conditions — diabetes, cardiovascular disease, chronic pain and fatigue, and genitourinary changes such as vaginal dryness or atrophy that make sex uncomfortable. Psychological factors — depression, anxiety, chronic stress, body-image concerns, and a history of trauma. Relationship and lifestyle factors — sleep debt and fatigue, alcohol, relationship conflict, and simple lack of unpressured time and communication. When one of these is the real driver, the supplement question becomes secondary—treating the cause (adjusting a medication, addressing atrophy, treating depression, protecting sleep) tends to do far more than any capsule. Hypoactive sexual desire disorder (HSDD), the formal diagnosis, requires that low desire be persistent and personally distressing, and that other explanations have been reasonably excluded. How to Read the Evidence: Effect Size and the Placebo Problem Two ideas make the rest of this article interpretable. First, effect size (Cohen's d) describes how large a treatment's benefit is beyond placebo: roughly 0.2 is small, 0.5 medium, and 0.8 large. Second, the placebo response in sexual-function trials is unusually high—women in placebo arms routinely report meaningful improvement, because expectation, attention, and simply focusing on intimacy all have genuine effects. Any product's real-world value is only the slice above that placebo response, which is why so many "it worked for me" reports do not survive a controlled trial. Most female sexual-function trials measure outcomes with the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS). Keep those two anchors—effect size and the placebo curve—in mind as we go. The Prescription Options: Best Data, Still Modest Flibanserin (Addyi) A daily oral medication acting on serotonin and dopamine pathways in the brain, approved for acquired, generalized HSDD in premenopausal women. Across the pivotal trials, the effect versus placebo landed in the small range—improvements in desire and reductions in distress with effect sizes around 0.3 to 0.4—and a 2016 systematic review and meta-analysis concluded the benefit amounted to roughly half of one additional satisfying sexual event per month over placebo. The FDA's own review described the average treatment effect as small while noting some women found it clinically meaningful. The safety caveats are not trivial: flibanserin can cause central-nervous-system depression, and this risk rises sharply with alcohol and with drugs that raise its blood levels. Bremelanotide (Vyleesi) An on-demand injectable melanocortin-receptor agonist, self-administered before anticipated activity, also approved for premenopausal HSDD. In the RECONNECT phase 3 trials, it significantly improved desire and reduced distress versus placebo, again with small effect sizes (roughly 0.3 relative to placebo). Nausea is common, and transient blood-pressure elevation means it is avoided in women with uncontrolled hypertension or established cardiovascular disease. The takeaway is not that these drugs fail—they have the most rigorous evidence base in the field—but that even the best-studied options move the needle modestly. That reframes expectations for anything sold without a prescription. The Botanicals and Nutraceuticals, Graded The table below sorts the common ingredients by the strength and consistency of their human trial evidence for female desire or sexual function, not by popularity or marketing. "Reasonable signal" still means small, short trials—it is a relative grade within a low-evidence field. Tier Ingredient & what the trials show Best-fit context Most consistent signal Saffron, ashwagandha, and a tribulus RCT each showed FSFI improvement vs placebo in randomized trials. Maca helped orgasm/arousal chiefly in peri- and postmenopausal women and in SSRI-induced dysfunction. Menopausal transition; SSRI-associated low desire Modest / context-dependent L-arginine combination products (e.g., ArginMax) improved self-reported desire across menopausal status. Fenugreek extract (Libifem) showed benefit in one RCT. Chasteberry has a small signal in postmenopausal women. Women wanting a lower-risk first step Mixed / inconclusive Ginseng, ginkgo. Red clover has solid evidence for hot flushes but only indirect, weak data for desire itself. Effects are inconsistent across studies. Not reliable as a primary strategy Evidence points the other way Oral DHEA: the best randomized trial in postmenopausal women with low libido found no significant benefit over placebo at 50 mg/day, with androgenic side effects (acne, hair growth). Often listed as "supported"—the controlled data don't back that for oral DHEA and low desire. Not supported for this use A closer look at the standouts Saffron (Crocus sativus). Randomized, placebo-controlled trials—including in women with fluoxetine-induced sexual dysfunction—have shown improvement in FSFI scores, and a meta-analysis supports a benefit across sexual-function domains. Among botanicals, this is some of the more reproducible signal. Ashwagandha (Withania somnifera). A placebo-controlled RCT in women with low FSFI scores found significant gains in total FSFI, arousal, lubrication, orgasm, and satisfaction. Plausibly works partly through stress and cortisol pathways rather than hormones directly. Maca (Lepidium meyenii). A systematic review called the overall evidence limited, but the signal is strongest in specific groups: menopausal women, and women with SSRI-induced dysfunction, where a small trial showed benefit concentrated in postmenopausal participants. Notably, it does not appear to raise testosterone. Tribulus terrestris. A randomized, double-blind trial in women with HSDD reported significant FSFI improvement over four weeks. Encouraging but short, and single-trial evidence should be held loosely. L-arginine combinations. Products combining L-arginine with ginseng, ginkgo, and other botanicals (ArginMax) improved self-reported desire and satisfaction across menopausal status in company-associated trials; a later systematic review found L-arginine-based formulas the best-studied of this category, though blinding and funding limit confidence. DHEA—the honest correction. Oral DHEA is frequently listed among "ingredients with support," but the strongest randomized trial in postmenopausal women with low libido found no significant improvement over placebo, while causing androgenic side effects. (A separate, FDA-approved intravaginal form, prasterone, is used for painful sex from vaginal atrophy—a different problem than low desire.) Who Might Reasonably Try Them—And Who Should Not May be reasonable candidates Peri- and postmenopausal women whose desire change tracks with hormonal transition, once atrophy and other drivers are addressed. Women with no identifiable treatable cause who want a lower-risk first step before, or alongside, discussing prescription options with a clinician. Women with SSRI-associated low desire, where saffron and maca have the most relevant trial data—though adjusting the antidepressant with the prescriber is often the higher-yield move. Should generally avoid, or proceed only with medical oversight Anyone pregnant or breastfeeding. Women on blood thinners, or with uncontrolled cardiovascular disease. Women with hormone-sensitive cancers (breast, uterine), given phytoestrogenic ingredients such as red clover. Women with bipolar disorder or a seizure disorder, and those taking MAOIs. Women taking SSRIs, insulin, or other medications with meaningful interaction potential—coordinate first. Anyone approaching surgery (bleeding and anesthesia interactions). Anyone already taking flibanserin, which interacts dangerously with alcohol and can be affected by botanicals such as ginkgo and St. John's wort. The Clinical Bottom Line Libido supplements are best understood as a low-probability, generally-low-risk experiment—reasonable to try in the right person, but not a substitute for finding the actual driver of low desire. If a specific cause exists, treating it is almost always more effective than any capsule. If a woman wants to try a supplement, saffron and ashwagandha have the most defensible evidence, maca is worth considering in the menopausal or SSRI context, and oral DHEA is the one commonly-promoted ingredient the controlled data do not support for this purpose. And because "natural" is not the same as "inert," the safety and interaction screen above matters as much as the efficacy question. If you would like a personalized, evidence-based evaluation of low desire—including the hormonal, medication, and lifestyle contributors that supplements can't fix—my integrative practice is at www.directintegrativecare.com. Selected References 1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899–908. 2. Jaspers L, Feys F, Bramer WM, et al. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2016;176(4):453–462. 3. U.S. FDA, Center for Drug Evaluation and Research. Flibanserin (Addyi) Summary Review, NDA 022526. 2015. 4. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol. 2013;28(1):54–60. 5. Ajgaonkar A, Jain M, Debnath K. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract for Improvement of Sexual Health in Healthy Women: A Prospective, Randomized, Placebo-Controlled Study. Cureus. 2022;14(10):e30787. 6. Dording CM, Schettler PJ, Dalton ED, et al. A Double-Blind Placebo-Controlled Trial of Maca Root as Treatment for Antidepressant-Induced Sexual Dysfunction in Women. Evid Based Complement Alternat Med. 2015;2015:949036. 7. Shin BC, Lee MS, Yang EJ, Lim HS, Ernst E. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med. 2010;10:44. 8. Akhtari E, Raisi F, Keshavarz M, et al. Tribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo-controlled study. Daru. 2014;22(1):40. 9. Ito TY, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther. 2001;27(5):541–549. 10. Ito TY, Polan ML, Whipple B, Trant AS. The enhancement of female sexual function with ArginMax among women differing in menopausal status. J Sex Marital Ther. 2006;32(5):369–378. 11. Systematic Review of l-Arginine for the Treatment of Hypoactive Sexual Desire Disorder and Related Conditions in Women. Pharmacy (Basel). 2021;9(2):71. 12. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med. 2009;6(9):2579–2590. 13. Kanadys W, Barańska A, Błaszczuk A, et al. Evaluation of Clinical Meaningfulness of Red Clover Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis. Nutrients. 2021;13(4):1258. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed a fellowship under Dr. Andrew Weil at the University of Arizona and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and more than 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Low Dose Naltrexone in San Antonio: Why It Works, and Why Dr. Kim Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Living with a chronic condition can feel like working through a to-do list that never quite ends. You try a medication, a symptom quiets down for a while, and the thing underneath it never really moves. If that sounds familiar, Low Dose Naltrexone — usually just called LDN — is worth understanding, because it starts from a different place. Instead of masking a symptom, it asks the body to recalibrate. I've spent more than twenty years practicing integrative and functional medicine, and I lead one of the largest online LDN education communities anywhere. Let me walk you through what LDN is, why so many people here in San Antonio are asking about it, and what makes the care model different. What LDN Actually Does Naltrexone was first approved at high doses — around 50 mg — to treat alcohol and opioid dependence. LDN uses a small fraction of that, typically 1 to 4.5 mg once daily. At that low dose, it behaves in a completely different way. Research suggests it briefly and gently blocks opioid receptors, which prompts the body to raise its own endorphin levels and to calm an overactive inflammatory response in the nervous system, partly by modulating a receptor called Toll-like receptor 4 (Toljan & Vrooman, 2018). Reviews of the chronic-pain literature describe LDN as acting less like a painkiller and more like a novel anti-inflammatory that quiets the glial cells of the central nervous system (Younger, Parkitny & McLain, 2014). A useful way to picture it: LDN doesn't drown out the signal — it helps retune the system that keeps sending it. Why People in San Antonio Are Asking About It The interest isn't hype. LDN is inexpensive, taken once a day at bedtime, and generally well tolerated, which makes it appealing to people who've grown wary of medications that trade one problem for another. What it does require is a physician who understands the nuance — the right starting dose, how to titrate over time, how it fits alongside the rest of your health picture, and where a compounding pharmacy comes in. That's exactly where the choice of provider matters. Why Dr. Kim Here's the honest differentiator. Plenty of clinics can write an LDN prescription. Far fewer have spent years living inside the LDN world. I founded and lead an online LDN community with more than 9,000 members, I've written two books on LDN, and I've watched this therapy help real people across a wide range of conditions. That depth changes the quality of the conversation you and I get to have. How the practice is built matters just as much. Care through www.directintegrativecare.com is membership-based and insurance-free by design — which means appointments aren't rushed, and the plan is genuinely yours rather than a template. We start by understanding your full history and looking for root causes, not just the loudest symptom. When LDN is a fit, it becomes one carefully chosen piece of a larger, personalized plan. Conditions LDN May Help LDN has shown the most promise in conditions that involve immune dysregulation and inflammation. In published reports and reviews, that includes: Autoimmune conditions such as multiple sclerosis Fibromyalgia and other chronic pain syndromes Chronic fatigue syndrome Inflammatory bowel conditions, including Crohn's disease Complex regional pain syndrome LDN isn't a cure, and it isn't right for everyone. But for the right person, it can be a meaningful part of feeling like themselves again. What to Expect We begin with a thorough consultation — your history, your goals, and whether LDN makes sense for you. If it does, we typically start low (often around 1.5 mg at bedtime) and adjust gradually. We follow up, track your response, and fine-tune. Some people notice vivid dreams early on; these usually settle. Benefits tend to build over weeks to months, so patience and communication are part of the process. Learn More: Books by Dr. Kim If you'd like to go deeper, I've written two books on Low Dose Naltrexone, both available on Amazon: The Low Dose Naltrexone (LDN) Primer: 2026 Edition — a 133-page, plain-language guide for anyone new to LDN, covering how it works, what to expect, and its use in conditions such as fibromyalgia, Long COVID, and Hashimoto's thyroiditis. LDN for Clinicians — a comprehensive clinical reference for practitioners who want to understand and prescribe LDN with confidence. Taking the Next Step If you're ready to explore a root-cause approach to a chronic condition — and to work with a physician who knows LDN inside and out — I'd be glad to help. You can learn more and request a consultation at www.directintegrativecare.com. Your body has a real capacity to heal. Sometimes it just needs the right key. In health, Yoon Hang Kim, MD, MPH About Dr. Kim Dr. Yoon Hang “John” Kim is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed a fellowship in integrative medicine under Dr. Andrew Weil at the University of Arizona and holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, along with medical acupuncture training. He specializes in Low Dose Naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and more than 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com References Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82.

Why Choose Yoon Hang Kim, MD, MPH for Functional Medicine in San Antonio Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com If you have been searching for a functional medicine doctor in San Antonio, you have probably noticed that every clinic's website sounds the same: root cause, personalized care, advanced testing. Those are the right words — but words alone do not tell you whether a provider will actually deliver the depth of expertise, accessibility, and sustained partnership your health requires. This post explains why Dr. Yoon Hang Kim's membership-based, insurance-free practice stands apart from the crowd — and why a concierge model may be exactly what chronic-illness care demands. Table of Contents 1. The Problem with the Standard Functional Medicine Search 2. Who Is Yoon Hang Kim, MD, MPH? 3. The Membership Model: Why It Matters 4. Market-Rate Pricing, Far Beyond Market-Rate Access 5. Telemedicine Reach Across Multiple States 6. Comparing Care Models 7. Who Benefits Most from This Practice? 8. What Sets This Apart in San Antonio 9. Key Takeaways 10. Frequently Asked Questions 11. Taking the Next Step The Problem with the Standard Functional Medicine Search A quick search for "functional medicine San Antonio" returns dozens of results. Many are large multi-provider clinics running high-volume schedules. Others are cash-pay practices that still rely on per-visit billing, meaning your access to your doctor depends on whether you can book the next available slot — often weeks out. In both models, the relationship is transactional: you buy an appointment, you receive a service, and between visits you are largely on your own. For people with complex, overlapping conditions — autoimmune disease, mast cell activation syndrome (MCAS), chronic fatigue, mold toxicity, POTS, or fibromyalgia — that episodic model falls short. These conditions do not wait for your next scheduled appointment. Questions surface between visits, lab results need interpretation in real time, and treatment plans require continuous fine-tuning. The gap between what clients need and what most practices deliver is where Dr. Kim's model fills a critical void. Who Is Yoon Hang Kim, MD, MPH? Dr. Kim brings more than 20 years of clinical experience in integrative and functional medicine. His training includes an Osher Fellowship under Dr. Andrew Weil at the University of Arizona Center for Integrative Medicine — widely considered the gold standard in integrative medical education. He holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, a medical acupuncture certification from UCLA, and IFM (Institute for Functional Medicine Scholarship Recipient. His clinical expertise spans complex chronic illness including autoimmune conditions, MCAS, mold toxicity and CIRS, chronic fatigue syndrome, fibromyalgia, POTS, integrative oncology, and low-dose naltrexone (LDN) therapy. Dr. Kim is an internationally recognized authority on LDN, having authored multiple books on the subject — including the clinician textbook LDN for Clinicians, Researchers, and Empowered Patients — published over 20 peer-reviewed articles, and founded the LDN Support Group, a community of more than 9,000 members. He has previously served as Medical Director of Integrative Oncology at Miami Cancer Institute and as Director of the Integrative Medicine Program at the University of Kansas Medical Center. Dr. Kim's depth of training, clinical volume, and academic contributions place him among the most credentialed integrative and functional medicine physicians practicing in Texas today. The Membership Model: Why It Matters The practice at www.directintegrativecare.com operates on a membership model — sometimes called direct primary care or concierge medicine — rather than conventional fee-for-service billing. Here is what that means in practice: ● Capped panel size. Dr. Kim limits his active client panel to 99 individuals. A typical primary care physician manages 2,000 to 3,000 clients; most concierge practices cap between 300 and 600. A smaller panel translates directly into longer visits, faster responses, and a physician who actually knows your case — not just your chart. ● Predictable monthly investment. Rather than being surprised by per-visit charges or unpredictable insurance co-pays, members pay a flat monthly fee that covers ongoing access to Dr. Kim. Full details are available on the fee schedule. This transparency eliminates the financial uncertainty that discourages many people from seeking the care they need. ● Insurance-free by design. The practice does not bill insurance. While that may sound counterintuitive, it is actually liberating — for both the client and the physician. Insurance dictates visit length, limits which tests can be ordered, and often delays referrals. Removing the insurance middleman means Dr. Kim can spend the time a case requires, order the labs a case demands without payer restrictions, and pursue the treatment strategy that serves the client rather than the payer. ● Continuous access, not episodic care. Membership means the relationship does not end when the visit does. Clients have ongoing communication access for questions, lab interpretation, and care coordination. This continuity is especially critical for conditions that fluctuate — like MCAS flares, hormonal shifts, or post-infectious syndromes — where waiting weeks for a follow-up appointment can mean unnecessary suffering. Market-Rate Pricing, Far Beyond Market-Rate Access Most concierge and membership practices limit their panels to somewhere between 300 and 600 clients. Even practices charging well above the national median typically cap between 200 and 400. Dr. Kim caps his panel at 99. That is the number that matters. Membership pricing at this practice sits within the ordinary national range for concierge and direct-care medicine — roughly $250 to $350 per month, with current tiers detailed on the fee schedule. What is not ordinary is what that fee buys: a panel three to six times smaller than the concierge norm. Fewer clients per physician is the structural variable that determines whether "personalized care" is a slogan or a daily reality. This is a deliberate philosophical choice. Dr. Kim's guiding principle is that sustainable health outcomes require a long-term partnership, not a one-off encounter. Building the practice around a small panel rather than around volume is what allows him to give each client the depth of attention their condition requires — and it is why membership is capped rather than open-ended. Telemedicine Reach Across Multiple States While Dr. Kim is based in San Antonio, the practice is built on a telemedicine-forward model that extends well beyond city limits. Dr. Kim holds active medical licenses in Texas, Iowa, Illinois, Missouri, Georgia, and Florida, enabling him to serve clients across a significant geographic footprint. Whether you are in Houston, Atlanta, Des Moines, or Jacksonville, you can access the same unhurried, membership-based care as someone sitting in Alamo Heights. For individuals outside these states or outside the United States, Dr. Kim also offers Educational Consultation Agreements — structured 30-minute video sessions that provide guidance within appropriate professional boundaries. This means that even if licensure limitations prevent a formal clinical relationship, you are not entirely shut out from Dr. Kim's expertise. Comparing Care Models The table below outlines how this practice differs from the two most common alternatives a San Antonio client is likely to encounter. Feature Insurance-Based Primary Care Typical Concierge Membership (This Practice) Panel size 2,000–3,000 clients 300–600 clients Capped at 99 Visit length 10–15 minutes 30–60 minutes Extended, unhurried Access between visits Phone tag / portal Direct, varies Ongoing direct access Billing model Insurance + copays Membership, often + insurance Flat monthly, insurance-free Care focus Symptom management Enhanced primary care Root-cause, longitudinal Complex chronic illness fit Limited Varies by provider Built for it Who Benefits Most from This Practice? Dr. Kim's practice is not designed to be all things to all people. It is specifically built for individuals who have complex, chronic health challenges and who have often felt failed by conventional medicine. If any of the following resonate, this model may be the right fit: ● You have been through multiple specialists without clear answers or meaningful improvement. ● You have an autoimmune diagnosis — or suspect one — and want a provider who looks beyond immunosuppression as the only strategy. ● You are dealing with MCAS, POTS, mold illness, chronic fatigue, or fibromyalgia and need a physician experienced with these specific conditions. ● You are a cancer survivor or active oncology client seeking integrative support alongside conventional treatment. ● You are interested in LDN therapy and want guidance from one of the foremost clinical experts in the field. ● You value a physician relationship built on partnership and communication, not assembly-line medicine. What Sets This Apart in San Antonio San Antonio has a growing number of integrative and functional medicine providers, and many are doing good work. But there are meaningful differences worth noting: ● Depth of specialization. Many functional medicine practices take a generalist approach — broad wellness optimization. Dr. Kim's practice is oriented toward complex chronic illness, which requires a different clinical skillset, a different testing philosophy, and a different tolerance for diagnostic ambiguity. ● Academic and research foundation. With over 20 peer-reviewed publications, multiple books, and national-level speaking engagements, Dr. Kim's clinical decisions are grounded in evidence — not trends. When he recommends a protocol, it is backed by literature he has personally evaluated and, in many cases, contributed to. ● Panel size discipline. It is easy for a practice to claim "personalized care." It is much harder to enforce the structural constraints — like a 99-client cap — that make personalized care actually possible. This is a practice that has chosen to stay small on purpose. ● Continuity and relationship. In a membership model, Dr. Kim is your physician over months and years, not for a single consultation. He tracks your trajectory, remembers your history, and adjusts your plan as your life and body change. That longitudinal relationship is where the real clinical value lives. Key Takeaways ● Root-cause, longitudinal care. The membership model means a capped panel, direct access, and a physician relationship measured in years, not visits. ● Insurance-free is liberating. Removing the payer removes restrictions on visit length, testing, and treatment strategy. ● Built for complexity. Autoimmune disease, MCAS, POTS, mold illness, integrative oncology, and LDN therapy are core areas of expertise. ● Reach across six states. Telemedicine care in TX, IA, IL, MO, GA, and FL, plus educational consultations for those elsewhere. ● Typical fee, atypical panel. Membership pricing sits in the ordinary concierge range, but the panel is capped at 99 rather than the customary 300 to 600. ● Get started. Call or text (210) 981-6106, or visit www.directintegrativecare.com. Frequently Asked Questions What does the membership include? Membership covers ongoing access to Dr. Kim — extended visits, communication between appointments, lab interpretation, and care coordination — under a flat monthly fee. Specific inclusions by tier are listed on the fee schedule. Do you take insurance? No. The practice is insurance-free by design, which allows Dr. Kim to determine visit length, testing, and treatment based on what your case requires rather than what a payer will authorize. Clients may still use insurance independently for outside labs, imaging, or medications. Can I see Dr. Kim if I live outside Texas? Yes, if you are in Iowa, Illinois, Missouri, Georgia, or Florida, where Dr. Kim is also licensed. For those outside these states or abroad, Educational Consultation Agreements offer a structured way to access his guidance within professional boundaries. How does the cost compare to other concierge practices? Membership here sits within the ordinary national range for concierge and direct-care medicine. The difference is not the price — it is the panel. Most concierge practices carry 300 to 600 clients per physician; Dr. Kim caps at 99. You are paying a typical membership fee for a substantially smaller panel and correspondingly greater access. Current tiers are listed on the fee schedule. How do I get started? Call or text (210) 981-6106, or visit www.directintegrativecare.com to review membership options and begin with a virtual assessment. Taking the Next Step If you are ready to move beyond symptom management and invest in a physician relationship built for the long haul, Dr. Yoon Hang Kim's practice may be the partnership you have been looking for. Call or text (210) 981-6106, or visit www.directintegrativecare.com to review membership options, see the fee schedule, and take the first step toward care designed around you — not around an insurance company's priorities. Disclaimer: This blog post is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided should not replace a consultation with a qualified healthcare provider. Individual results may vary. If you have questions about your health, please consult a licensed physician. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed his fellowship training at the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture (UCLA), and integrative & holistic medicine, along with IFM Scholar status. Dr. Kim specializes in low-dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He has authored 3 books, published over 20 peer-reviewed articles, and founded the LDN Support Group with more than 9,000 members. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

How to Approach Your Doctor About Low-Dose Naltrexone (LDN): A Patient's Guide to a Productive Conversation Written and medically reviewed by: Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Low-dose naltrexone (LDN) is used off-label for the conditions discussed below; it is not FDA-approved for any of them. All therapeutic decisions, including the use of LDN, should be made in consultation with a qualified healthcare provider who can evaluate individual circumstances. Nothing in this article creates a physician-patient relationship. Last updated: August 2026 The Short Answer If you believe low-dose naltrexone might help your condition, come prepared: bring published evidence, frame your request as a question rather than a demand, and understand why your physician may hesitate. This article gives you the tools to have that conversation — honestly, respectfully, and with the best available evidence in hand. Introduction One of the most common frustrations I hear from patients — in my own practice and through the LDN Support Group community of over 9,000 members — is not about LDN itself. It is about getting their doctor to consider prescribing it. The frustration is understandable. You have done your research. You have read about other patients whose chronic pain, autoimmune symptoms, or fatigue improved. You may have found peer-reviewed studies suggesting benefit for your specific condition. And yet, when you raise it with your physician, the response is often dismissive, noncommittal, or simply "I've never heard of that." This is not necessarily your doctor's fault, and it does not mean LDN is without merit. What it usually reflects is a systemic gap: the published evidence for LDN has grown considerably over the past decade, but it has not yet penetrated most standard medical training. Understanding why that gap exists — and knowing how to bridge it respectfully — is the purpose of this guide. At its core, this is a conversation about shared decision-making: the collaborative process in which patients and physicians bring different knowledge to the same table. You bring your experience of your illness. Your physician brings clinical training and the responsibility to evaluate evidence. Neither party has the full picture alone. The strategies in this article are designed to make that collaboration work [18,19]. Why Many Physicians Hesitate to Prescribe LDN Before preparing your approach, it helps to understand the legitimate reasons a physician might be reluctant. These are real clinical and professional considerations — not excuses — and acknowledging them during your conversation signals that you are an informed patient, not someone pushing a fringe remedy. Unfamiliarity The most common barrier is simply not knowing enough about LDN. Naltrexone is taught in medical school as a 50 mg medication for opioid and alcohol use disorders. The idea that one-tenth of that dose might exert entirely different pharmacological effects — through TLR4 antagonism on microglial cells rather than classical opioid receptor blockade — is counterintuitive [1,2]. A 2022 multisite survey found that the most commonly reported barrier to prescribing naltrexone among non-addiction-trained physicians was unfamiliarity with its therapeutic uses [3]. Only about one in four surveyed prescribers had written a naltrexone prescription in the preceding three months — and that survey examined the standard 50 mg dose, not the low-dose applications [3]. The knowledge gap for LDN is far wider. Off-Label Prescribing Concerns LDN is not FDA-approved for any of the conditions it is commonly used to treat — fibromyalgia, Crohn's disease, multiple sclerosis, chronic pain, autoimmune conditions, or long COVID. This matters to physicians because prescribing something off-label requires confidence in the supporting evidence. Off-label prescribing is entirely legal and common — studies estimate that 21% to 38% of all outpatient prescriptions in the United States are off-label [4,5]. Gabapentin for neuropathic pain, amitriptyline for migraine prevention, and metformin for polycystic ovarian syndrome are all everyday off-label prescriptions most physicians write without hesitation. But when a physician has not reviewed the evidence for a particular off-label use, hesitation is rational, not obstructionist. Compounding Pharmacy Requirements Unlike most medications, LDN cannot be dispensed from a standard pharmacy. Naltrexone is only commercially available as 50 mg tablets (or injectable depot formulations for addiction), so low doses — typically 0.5 to 4.5 mg — must be prepared by a compounding pharmacy. This adds logistical complexity that many physicians have not navigated. Some do not know this pathway exists or how to write a prescription for a compounded medication. Insufficient Large-Scale Trial Evidence Physicians are trained to value randomized controlled trials above all other evidence, and the LDN literature has a real limitation: most positive studies are small. The landmark fibromyalgia pilot enrolled 10 participants [6], the crossover trial included 28 [7], and the Crohn's disease pilot involved 17 [8]. The largest and most rigorous fibromyalgia RCT to date — 99 women randomized to naltrexone or placebo for 12 weeks — did not find LDN superior to placebo on its primary pain endpoint, though adverse events were essentially identical between groups [9]. (That trial used a 6 mg dose, which is above the conventional LDN ceiling of 4.5 mg — a detail the LDN clinical community considers relevant, though it does not erase the result.) A physician who looks at this landscape and says "the evidence is promising but limited" is being honest, not dismissive. Concern About Interactions and Safety Monitoring The most important safety consideration is well-established: naltrexone at any dose blocks opioid receptors and will reduce or eliminate the effectiveness of opioid pain medications. Perioperative guidelines broadly recommend discontinuing oral naltrexone at least 72 hours before elective surgery, and after discontinuation, opioid responses can become unpredictable due to receptor upregulation [10,11]. Any patient taking LDN must carry this information and disclose it proactively to emergency, surgical, and anesthesia teams. This is a safety issue, not a preference. Preparing for the Conversation: What to Bring The difference between a productive conversation and a frustrating one often comes down to preparation. Organized, credible information signals respect for your physician's expertise while giving them the tools they need to evaluate LDN on its merits. Bring Published Evidence — Not Internet Forums Physicians respond to peer-reviewed literature. Anecdotes from Facebook groups, however heartfelt, do not carry clinical weight. Fortunately, the LDN evidence base has matured considerably. The foundational mechanistic review is Younger, Parkitny, and McLain (2014), which established that LDN operates via TLR4 antagonism on microglia — independent of classical opioid receptor effects [1]. Toljan and Vrooman (2018) provide a comprehensive clinical review covering mechanism, dosing, and evidence across multiple conditions [2]. Patten, Schultz, and Berlau (2018) focus specifically on the safety profile, which is consistently favorable [12]. The most recent overview — a 2023 scoping review in Pain Medicine — identified 47 studies across multiple chronic pain conditions [13]. Full citations with PubMed IDs are in the References section; any of these can be printed and handed to your physician. For condition-specific conversations: the strongest RCT data comes from Crohn's disease, where Smith et al. published an open-label pilot showing 67% remission rates [8] followed by a placebo-controlled trial demonstrating improved mucosal healing [14]. In fibromyalgia, earlier trials showed reduced pain severity and decreased pro-inflammatory cytokines [6,7,15], though as noted above, the largest RCT did not confirm superiority over placebo [9]. In multiple sclerosis, a pilot trial showed improvement in mental-health quality-of-life measures [16]. In long COVID and ME/CFS, a 2026 systematic review in BMJ Open found moderate-to-large favorable effect sizes for fatigue, pain, and sleep — while explicitly noting that no randomized controlled trials were identified and rating overall certainty of evidence as low [17]. Present this evidence honestly. The case for LDN is that it has a plausible mechanism, a favorable safety profile, and a growing but still-developing body of clinical evidence. That is a reasonable basis for a conversation — not a guarantee. Consider Gifting the LDN Primer I wrote the Low-Dose Naltrexone (LDN) Primer: 2026 Edition for exactly this situation — a concise, evidence-based introduction that any physician can read in a single sitting. It covers mechanism, conditions where evidence exists, realistic expectations about response rates, dosing, and what LDN cannot do. Chapter 11 includes a sample letter you can bring to your doctor and a practical guide to finding an LDN prescriber. The Primer is available on Amazon in Kindle and paperback: amazon.com/dp/B0GZ9R4667 Gifting the Primer to your physician shifts the dynamic. Instead of asking them to prescribe something they have never heard of, you are handing them a referenced book from a board-certified colleague and asking them to evaluate it on its merits. The book does the educational work so the conversation can focus on whether LDN is appropriate for you. About two-thirds of patients respond meaningfully to LDN; about one-third do not. The Primer names this openly and devotes a full chapter to what to do when standard LDN does not work. That candor is what builds physician trust. For clinicians and researchers seeking deeper discussion, the companion volume — LDN for Clinicians, Researchers, and Empowered Patients: Two Decades of Clinical Observation (2026 Edition) — offers sixteen chapters on pharmacology, evidence, and practical dosing frameworks. Use Free Educational Resources Not everyone wants to purchase a book, and not every physician needs one. The full library of referenced articles at www.ifmsynergy.com is available at no cost. Articles particularly useful for physician conversations include: LDN in Functional Medicine: A Practical Guide — Individualized dosing and clinical integration 15 Teaching Points from the LDN Support Group Pop-Up Live — Evidence-referenced review including the negative fibromyalgia RCT Integrating LDN Into a Multimodal Strategy for Interstitial Cystitis — 35 peer-reviewed references LDN, Emotional Distress, Neuropathy, and Mitochondrial Support — Pairing LDN with complementary strategies These articles include editor's notes where evidence diverges from clinical enthusiasm, negative trial results alongside positive ones, and explicit statements about what remains uncertain. That is the kind of resource a thoughtful physician can trust. How to Frame the Conversation Tone matters as much as content. Here are practical approaches drawn from my experience on both sides of the conversation. Lead With Your Symptoms, Not the Drug Start with what you are experiencing and what has not worked, not with "I want LDN." A physician is far more receptive to: "I have been dealing with [condition] for [duration]. I have tried [treatments X, Y, Z] without adequate improvement. In my research, I came across low-dose naltrexone and wanted to ask whether it might be appropriate for me." The first framing positions you as a partner. Contrast it with: "I read online that LDN can cure [condition] and I want you to prescribe it." The second positions you as someone who has already made the clinical decision and is asking the physician to sign off on it. Acknowledge What You Do Not Know Something like: "I understand the evidence is still developing and that LDN is off-label — I am not asking you to promise it will work, I am asking whether it is reasonable to try." This communicates intellectual honesty and makes the physician more willing to engage. Offer Materials and Time Hand your physician something they can review at their own pace: "I brought this book [or article] that covers the evidence and dosing. Would you be willing to review it and discuss at our next visit?" This removes the pressure of an on-the-spot decision and respects the reality that a 15-minute appointment is not sufficient to evaluate an unfamiliar therapy. Bring the Safety Data One of LDN's strongest arguments is its safety profile. Adverse events across the published literature are consistently mild and typically transient: vivid dreams, mild sleep disturbance, headache, nausea [1,2,12]. In the largest fibromyalgia RCT, adverse event rates were essentially identical between the LDN group (84%) and placebo group (86%) [9]. A physician is more likely to try a therapy with a favorable risk-benefit ratio, even when the efficacy evidence is still developing. If Your Doctor Says No A refusal is not necessarily the end of the conversation. "I'm not comfortable prescribing something I don't know enough about." Respect this — it is honest. Offer the Primer or a review article and ask whether they would be willing to revisit the discussion after reviewing the material. If they say yes, follow up. "There isn't enough evidence." Partly true and partly a matter of perspective. Acknowledge the limitation while noting that the existing evidence — including the 2023 scoping review covering 47 studies [13] and condition-specific RCTs in Crohn's disease [8,14] — has been substantial enough that Stanford, the University of Alabama at Birmingham, and Dartmouth have all launched clinical trials evaluating LDN. The absence of large Phase III trials reflects the economics of generic medications — no pharmaceutical company will fund a $50 million trial for a drug they cannot patent — not a verdict on efficacy. "I don't know how to prescribe it." This is a practical barrier, not a philosophical one. LDN must be obtained from a compounding pharmacy. Typical starting doses are 0.5 to 1.5 mg daily, titrated slowly. The Primer covers prescribing details. The LDN Research Trust (ldnresearchtrust.org) also maintains resources for prescribers. If your physician remains unwilling, consider seeking an integrative or functional medicine physician with LDN experience. The LDN Support Group community is an excellent resource for connecting with knowledgeable prescribers. Calling local compounding pharmacies and asking which physicians in your area prescribe LDN is another practical strategy outlined in Chapter 11 of the Primer. What Not to Do Do not present LDN as a miracle cure. It is not. Overclaiming erodes your credibility and your physician's willingness to engage. Do not self-prescribe. Purchasing naltrexone from unregulated online sources and titrating without medical supervision is unsafe. LDN requires a prescription, a reputable compounding pharmacy, and clinical oversight — particularly for monitoring drug interactions, coordinating perioperative management, and adjusting dosing. Do not threaten or issue ultimatums. "If you won't prescribe this, I'll find someone who will" — even if true — poisons the relationship and confirms every negative assumption about internet-educated patients. Do not conflate your experience with evidence. If you have tried LDN through another provider and it helped, share that as your personal experience, not as proof that it works for everyone. Physicians respect the distinction. A Note About Shared Decision-Making The modern medical literature recognizes shared decision-making as the standard for clinical care [18,19]. This is mainstream medical ethics, not a radical concept. What it means practically: you have the right to bring information, ask questions, and participate in decisions about your care. Your physician has the responsibility to evaluate that information against their clinical knowledge and explain their reasoning. Both parties carry obligations. The patient who refuses to hear "no" is not practicing shared decision-making. Neither is the physician who refuses to hear the question. LDN sits in a space well-suited to shared decision-making: a therapy with a plausible mechanism, a growing evidence base, a favorable safety profile, and enough uncertainty that the patient's values and willingness to try something off-label are legitimately relevant to the clinical decision. Frequently Asked Questions Is it legal for my doctor to prescribe LDN off-label? Yes. Off-label prescribing is entirely legal in the United States and accounts for an estimated 21% to 38% of all outpatient prescriptions [4,5]. Any licensed physician can prescribe naltrexone at any dose for any condition they deem clinically appropriate. Where do I get LDN if my doctor prescribes it? LDN must be obtained from a compounding pharmacy, since naltrexone is only commercially available as 50 mg tablets. Your physician writes a prescription specifying the dose (commonly 0.5–4.5 mg), and the compounding pharmacy prepares it. Many compounding pharmacies ship nationwide. Can I take LDN with my current medications? LDN is contraindicated with opioid medications — naltrexone blocks opioid receptors and will reduce or eliminate opioid analgesia. Patients on opioids must work with their prescriber to discontinue opioids before starting LDN. Most other medications are compatible, but always disclose your full medication list [10,11]. How long does LDN take to work? Response timelines vary. Some patients notice improvement within weeks; others require two to three months. If there is no meaningful response after an adequate trial at the appropriate dose, LDN may not be the right tool for that individual. What if my doctor says no? See the detailed section above. In short: respect their reasoning, offer educational materials, and ask whether they would be willing to revisit the conversation. If they remain unwilling, an integrative or functional medicine physician with LDN experience may be a better fit. Summary Table Topic Key Point Most common physician barrier Unfamiliarity — LDN is not taught in standard medical training Off-label status Legal and routine; 21–38% of all U.S. prescriptions are off-label Strongest condition-specific evidence Crohn's disease (RCTs showing remission and mucosal healing) Broadest evidence survey 47 studies identified across a 2023 scoping review of centralized pain conditions Honest limitation Largest fibromyalgia RCT (6 mg dose) did not find superiority over placebo on primary pain outcome Safety profile Consistently favorable; adverse events mild and typically transient Critical safety note LDN blocks opioid receptors — must disclose to surgical/emergency teams Must be obtained from A compounding pharmacy (not available as a commercial low-dose product) Typical starting dose 0.5–1.5 mg daily, titrated slowly and individualized Response rate Approximately two-thirds respond meaningfully; one-third do not Best resource for physicians LDN Primer: 2026 Edition (Amazon) or free articles at www.ifmsynergy.com Best resource for finding a prescriber LDN Support Group community; local compounding pharmacies #LDN #LowDoseNaltrexone #LDNPrimer #PatientAdvocacy #SharedDecisionMaking #OffLabelPrescribing #IntegrativeMedicine #FunctionalMedicine #ChronicPain #Fibromyalgia #AutoimmuneDisease #CrohnsDisease #LongCOVID #MECFS #MCAS #Neuroinflammation #DrYoonHangKim #IFMSynergy #LDNSupportGroup #EvidenceBasedMedicine References 1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250 2. Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMID: 30248938 3. Lenz JG, Kjellgren RW, Hester BD, et al. Assessing naltrexone prescribing and barriers to initiation for alcohol use disorder: a multidisciplinary, multisite survey. Ment Health Clin. 2022;12(3):174–179. doi:10.9740/mhc.2022.06.174. PMID: 35619618 4. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021–1026. doi:10.1001/archinte.166.9.1021. PMID: 16682577 5. Bradford WD, Turner JL, Williams JW. Off-label use of pharmaceuticals: a detection controlled estimation approach. J Ind Econ. 2018;66(4):866–903. doi:10.1111/joie.12189. 6. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x. PMID: 19453963 7. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734. PMID: 23359310 8. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820–828. doi:10.1111/j.1572-0241.2007.01045.x. PMID: 17222320 9. Due Bruun K, Christensen R, Amris K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024;6(1):e31–e39. doi:10.1016/S2665-9913(23)00278-3. PMID: 38258677 10. Agency for Healthcare Research and Quality (AHRQ) PSNet. A painful medication reconciliation mishap — perioperative naltrexone management. psnet.ahrq.gov 11. Whately Y, et al. Perioperative management of patients on naltrexone. Australian and New Zealand College of Anaesthetists resource. ANZCA 12. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389. doi:10.1002/phar.2086. PMID: 29377216 13. Rupp A, Young E, Chadwick AL. Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023;24(11):1270–1281. doi:10.1093/pm/pnad074. PMID: 37302106 14. Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56(7):2088–2097. doi:10.1007/s10620-011-1653-7. PMID: 21380937 15. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016. PMID: 28536359 16. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145–150. doi:10.1002/ana.22006. PMID: 20695007 17. Byambasuren O, Atkins TJ, Baptista S, Glasziou P, Chakraborty S. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ Open. 2026;16:e111253. doi:10.1136/bmjopen-2025-111253. 18. Stiggelbout AM, Van der Weijden T, De Wit MPT, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ. 2012;344:e256. doi:10.1136/bmj.e256. PMID: 22286508 19. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–1367. doi:10.1007/s11606-012-2077-6. PMID: 22618581 All references verified against PubMed or publisher records. Citations reflect the strength and limitations of the underlying evidence, including trials with negative as well as positive results. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience spanning preventive medicine, integrative and functional medicine, medical acupuncture, and integrative holistic medicine. A fellowship-trained graduate of the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil, Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of the LDN Primer: 2026 Edition and LDN for Clinicians, Researchers, and Empowered Patients: Two Decades of Clinical Observation (2026 Edition), and has published more than 20 articles in integrative medicine. Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com Related Reading on IFMSynergy.com Low Dose Naltrexone (LDN) in Functional Medicine: A Practical Guide by Dr. Yoon Hang Kim 15 Teaching Points from the LDN Support Group Pop-Up Live — An Evidence-Referenced Review A Functional Medicine Approach to Interstitial Cystitis: Integrating Low-Dose Naltrexone Into a Multimodal Strategy LDN, Emotional Distress, Neuropathy, Chronic Fatigue Syndrome, and Mitochondrial Support Berkson's ALA/LDN Protocol in Integrative Oncology The Endorphin Depletion Hypothesis in CFS/ME SEO Keywords: How to ask your doctor about LDN, low dose naltrexone prescription, LDN Primer book, Dr Yoon Hang Kim, LDN patient advocacy, off-label prescribing LDN, how to get LDN prescribed, low dose naltrexone doctor, LDN evidence for physicians, ifmsynergy LDN, integrative medicine San Antonio, LDN support group, LDN dosing guide, approach doctor about LDN

The 2026 Healthcare Cost Crisis And Why Direct Care May Be the Answer You've Been Looking For By Yoon Hang "John" Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Disclaimer: This article is for informational and educational purposes only and does not constitute medical, financial, or legal advice. The information presented reflects publicly available data and the author's professional perspective. Readers should consult qualified professionals for decisions about healthcare coverage. Disclosure: The author is the founder and sole physician of Direct Integrative Care (www.directintegrativecare.com), a membership-based telemedicine practice discussed in this article. He has no financial relationships with any other organizations mentioned, including DPC Frontier, Green Imaging, Surgery Center of Oklahoma, Sedera, or any health sharing community. If you've started shopping for health insurance for 2026, you've likely experienced something that can only be described as sticker shock. For many Americans—particularly those on Affordable Care Act marketplace plans—this year marks a painful turning point. The numbers are stark, and they demand our attention—not just as clients and consumers, but as people who deserve better options for taking care of our health. As a physician who has spent over twenty years in integrative medicine, I've watched healthcare costs steadily climb while the system becomes increasingly disconnected from what clients actually need. But 2026 feels different. This year, we're witnessing a perfect storm of expiring subsidies, rising premiums, and systemic inflation that's forcing many of us to rethink everything we thought we knew about accessing healthcare. What's Driving the 2026 Cost Spike The primary driver of this year's dramatic premium increases is the expiration of enhanced ACA premium tax credits on December 31, 2025. These temporary extra subsidies—first enacted through the American Rescue Plan Act of 2021 and later extended under the Inflation Reduction Act—provided crucial financial relief to millions of marketplace enrollees. Without congressional action to extend them, that support vanished at the start of 2026. But here's what makes 2026 particularly challenging: insurers simultaneously raised their underlying premiums to account for higher medical costs, hospital expenses, prescription drug prices, GLP-1 medication spending, and general inflation. So enrollees are getting hit from both directions—they're losing the subsidies that made coverage affordable while the base cost of that coverage climbs higher than ever. The Numbers Tell a Sobering Story According to the Kaiser Family Foundation (KFF), subsidized ACA marketplace enrollees saw their average annual premium payments rise approximately 114 percent in 2026—from an average of $888 in 2025 to $1,904. That's not a typo. Premiums more than doubled for many families. KFF's more recent analysis (July 2026) found that actual premium payments rose by an average of 58 percent, lower than the projected 114 percent because many enrollees bought down to higher-deductible plans to manage costs. Families USA reports that individual market premiums—including Obamacare and other non-group plans—averaged approximately 26 percent higher in 2026 than the previous year, and that's before accounting for the loss of federal subsidies. Their July 2026 premium tracker confirmed a cumulative average increase of 25.5 percent. When you layer the subsidy expiration on top of those rate increases, the impact becomes truly staggering. The Urban Institute projected that 4.8 million Americans would become uninsured as a direct result of the subsidy expiration—a 21 percent increase in the national uninsured population. Their modeling also projected a $7.7 billion increase in demand for uncompensated care in 2026. A separate KFF analysis found that ACA Marketplace enrollment could fall from 22.3 million in 2025 to approximately 16.5 to 17.5 million in 2026. As of mid-2026, those projections are proving accurate: Families USA confirmed in July 2026 that approximately 4 million enrollees have already dropped coverage, and the organization warned that a shrinking, sicker risk pool would push premiums even higher in 2027—with early filings already showing another round of double-digit increases. Texas: Ground Zero for Premium Shock Here in Texas, where I practice telemedicine serving clients in the San Antonio area and beyond, the situation is especially acute. Texas reached a record 4.17 million ACA marketplace plan selections during the 2026 open enrollment period, according to Rice University's Baker Institute and Centers for Medicare and Medicaid Services (CMS) data—making it one of the largest ACA enrollee populations in the country. The Texas Tribune reported that health insurance companies requested an average premium increase of 24 percent for ACA plans in Texas in 2026—the largest since 2018, when average premiums rose 35 percent. KFF projects that Texans using ACA tax credits saw premiums rise by an average of 115 percent, or roughly $456 per year. Data from ACA Signups documented that while Texas was one of the few states where plan selections actually increased (by about 5.2 percent), over 2.6 million ACA exchange enrollees nationwide had already been priced out of the market as of February 2026. Texas 2036 analysis notes that while roughly 75 percent of current enrollees—about 3.1 million Texans with incomes below 200 percent of the Federal Poverty Level—still have access to low-cost or $0-premium plans, the expiration hits middle-income enrollees especially hard. Texas Senate Bill 1296, passed in 2021, allows the state to benefit more from federal subsidies than states without similar rules, helping keep both bronze and gold plans somewhat more affordable. But for those above the subsidy cliff, the impact remains severe. A Houston-area analysis suggests that while Texans can expect significantly higher 2026 ACA premiums, some may be able to soften the blow by switching metal tiers, shopping across insurers, or exploring high-deductible plans compatible with Health Savings Accounts (HSAs). Indeed, CMS data shows that Texas consumers responded to rising prices by actively switching from Silver plans to less expensive Bronze plans. Yet even those record plan selections mask a harder reality. Federal data released in July 2026 shows that only 79 percent of those 4.17 million Texans who selected plans actually paid their first premium—meaning nearly 900,000 Texans signed up but could not or did not follow through. Effectuated enrollment fell to 3.28 million, a 4 percent decline from 2025 and the first drop since 2019. Nationally, the picture is similar: Families USA confirmed in July 2026 that roughly 4 million enrollees have already dropped ACA coverage, and the number continues to grow. Let me be honest with you: the traditional workarounds are band-aids on a much larger wound. Switching to a bronze plan or raising your deductible might reduce your monthly premium, but it often means trading one form of financial anxiety for another—the fear that any significant health event could leave you facing thousands of dollars in out-of-pocket costs. KFF found that average ACA deductibles surged 37 percent to a record $3,786 in 2026, largely because of the shift from silver to bronze plans. Employer Plans Aren't Immune If you're fortunate enough to have employer-sponsored coverage, you might think you're insulated from these increases. Unfortunately, the data suggests otherwise. Mercer's 2025 National Survey of Employer-Sponsored Health Plans—based on responses from over 1,700 U.S. employers—projects that total health benefit costs per employee will rise 6.5 percent on average in 2026, the highest increase since 2010 and the fourth consecutive year of elevated cost growth. Without employer cost-management measures, the increase would have been nearly 9 percent. A subsequent Mercer report projects costs rising 6.7 percent, pushing average per-employee costs above $18,500. For small businesses and their employees, the outlook is even more challenging. The Peterson-KFF Health System Tracker analyzed preliminary rate filings from 318 small group insurers across all 50 states and Washington, D.C., finding a median proposed premium increase of 11 percent for 2026. A deeper review of 16 states showed a median increase of 12 percent, with insurers citing rising healthcare costs (estimated at about 9 percent) as the primary driver, alongside factors including GLP-1 medication costs, labor shortages, and shrinking risk pools. SHRM (the Society for Human Resource Management) reported that these increases signal mounting pressure on employers' healthcare budgets, with 59 percent of surveyed employers planning cost-cutting changes to their plans in 2026—up from 48 percent in 2025. For many workers, this means higher payroll deductions, higher deductibles, narrower networks, and the uncomfortable realization that "having insurance" doesn't necessarily mean being able to afford care. Taking Finances Out of the Healing Equation This brings me to a question I've been wrestling with for years: How can physicians and clients truly work together when finances constantly intrude on the healing relationship? In traditional healthcare, every interaction becomes a transaction. You call with a question—that's a billable event. You need a form filled out—another charge. You want to discuss your lab results in depth—better make sure it fits in your allotted appointment time, or you'll see it reflected in your bill. This transactional model doesn't just frustrate clients; it fundamentally undermines the kind of relationship that produces real healing. I know this intimately because I've lived it. In my previous integrative medicine practice, we billed cash for our services—what would be classified as cash fee-for-service. While I may have been serving my clients well in many ways, every time they engaged me, they got billed. We experimented with a membership model, but it never fully took off because we couldn't bring ourselves to completely abandon fee-for-service. We failed to take the plunge. That experience taught me something valuable: half-measures don't work. You can't create a truly client-centered practice while clinging to a billing model that inherently creates barriers between you and the people you're trying to help. The Direct Care Revolution So I studied the Direct Primary Care (DPC) model, and what I discovered surprised me. DPC is rapidly growing across the United States, offering an alternative that removes insurance companies from the primary care relationship entirely. When I left Kansas City about three years ago, a DPC practice had just opened. Today, it has several providers. That kind of growth speaks to a genuine hunger for something different. The premise is elegantly simple: clients pay a monthly membership fee—often comparable to what you might spend on an upscale gym membership—and in return, they get direct access to their physician without the constant intrusion of billing, coding, and insurance negotiations. No copays for visits. No surprise bills. No wondering whether your question is "worth" a call to the doctor's office. The growth data is remarkable—though it comes primarily from within the DPC ecosystem itself, which is worth noting. Hint Health, the leading membership management platform for DPC practices (and therefore an industry participant, not an independent research body), published its 2026 Direct Primary Care Trends Report drawing on data from over 2,700 DPC clinicians and 1.4 million members on its platform. The report found that DPC membership expanded 837 percent from 2017 to 2025, significantly outpacing U.S. population growth. By 2025, the model reached a density of 409 active members per 100,000 Americans, with practices now operating across 49 states. Hint Health's own tracking puts DPC at more than 3,600 distinct practices nationwide as of Q1 2025, growing at an annual rate above 19 percent since 2022. The Direct Primary Care Coalition reports that more than 2,300 DPC practices in 48 states and Washington, D.C. provide care to over 300,000 Americans, while the DPC Alliance's 2026 physician survey—the first major peer investigation since 2015—shows mature panel sizes clustering around the 400 to 700 client range. Texas leads the nation with more DPC clinics than any other state. The legislative momentum is equally striking. Approximately half of U.S. states have enacted laws explicitly exempting DPC arrangements from insurance regulation. And in a landmark policy shift, the One Big Beautiful Bill Act (signed into law July 4, 2025) explicitly recognizes Direct Primary Care memberships as qualified medical expenses under HSA rules—effective January 1, 2026. This means clients can now use pre-tax HSA dollars to pay for DPC subscriptions (up to $150 per month for individuals, $300 per month for families), and DPC enrollment no longer disqualifies individuals from contributing to an HSA. Bronze and Catastrophic ACA plans are also now HSA-eligible. The Direct Primary Care Coalition, along with individual physician advocates, championed this change for years through the bipartisan Primary Care Enhancement Act. Building an Ecosystem of Direct Care What excites me most about the direct care movement is that it extends far beyond primary care. An entire ecosystem is emerging that offers transparent, affordable pricing for services that have traditionally been shrouded in mystery and marked up beyond recognition. Laboratory Testing Many DPC practices offer deeply discounted labs—sometimes as low as $5 per test. Compare that to what you might pay through traditional insurance with high deductibles, and the savings become immediately apparent. Imaging Companies like Green Imaging (greenimaging.net) offer direct-pay MRIs, CT scans, ultrasounds, and other imaging services at a fraction of what hospitals typically charge. Their model purchases unused capacity at existing imaging centers—a network of over 4,500 facilities nationwide—and passes the savings along to clients, often 50 to 80 percent less than traditional out-of-pocket costs. A procedure that might cost $2,000 or more through the traditional system can often be obtained for a few hundred dollars. Surgery The Surgery Center of Oklahoma (surgerycenterok.com) has pioneered transparent, bundled pricing for procedures. They publish comprehensive, all-inclusive prices for every surgery online—something virtually unheard of in American healthcare. You know exactly what you'll pay before you walk through the door, and that price includes the facility fee, surgeon's fee, anesthesiologist's fee, and uncomplicated follow-up care. No surprise bills, ever. Specialty Care The Direct Specialty Care Alliance (dscalliance.org) is bringing the direct care model to specialists across the country—rheumatologists, cardiologists, endocrinologists, and others who are finding ways to practice outside the insurance system while providing accessible, affordable care. Health Sharing For catastrophic coverage and major medical events, health sharing organizations offer an alternative to traditional insurance. These are not insurance in the technical sense, but they provide a community-based approach to sharing medical costs that many find both affordable and aligned with their values. Members contribute monthly amounts, and when unexpected large medical expenses arise, the community shares those costs. Options range from faith-based communities like Samaritan Ministries and Medi-Share to secular options like Sedera (sedera.com). I've seen colleagues, their families, employees, and clients use these services with satisfaction. Important note: Health sharing organizations are not regulated like insurance and are not legally required to pay claims. Sharing is voluntary, not guaranteed, and experiences vary significantly. Some organizations have faced regulatory actions: in March 2025, the California Attorney General announced a $1.3 million settlement with Sedera for allegedly advertising what the state called unauthorized health plans to over 2,000 Californians. Sedera has since restructured under TruHealth Group and continues to operate in other states. Readers should carefully research any health sharing organization before enrolling, review complaint histories with their state insurance commissioner, and understand that these communities are not a substitute for regulated insurance coverage. Direct Integrative Care: My Answer to the Crisis Because I love integrative and functional medicine—and I view functional medicine as a specialization within integrative medicine that utilizes testing to explore potential root causes of illness—I wanted to create a sustainable model for those of us who believe in this approach to healing. Not just for the wealthy few who can afford boutique concierge practices, but for everyday people who deserve access to root-cause medicine. That's why I created www.directintegrativecare.com. It's an environment where I can work together with clients for a monthly fee—comparable to what you might pay for an upscale gym membership. In return, members receive 15 percent off supplements through Fullscript, access to wholesale-price functional medicine labs plus a modest 7 percent fee charged by our partner, and access to my professional services without the constant meter running on every interaction. This isn't about cutting corners or providing less care. It's about removing the financial friction that prevents genuine healing relationships from forming. When a client can message me with a question without worrying about whether they'll be billed for the privilege, we can have real conversations. When we're not constantly navigating insurance requirements, we can focus on what actually matters: understanding your unique situation and finding approaches that work for your body and your life. A Different Way Forward I won't pretend that direct care is a perfect solution for everyone. If you have a chronic condition requiring frequent hospitalizations, you'll still need some form of coverage for those major expenses. A health sharing organization, a high-deductible catastrophic plan, or—thanks to the One Big Beautiful Bill Act—a Bronze ACA plan paired with an HSA can fill that gap while still allowing you to benefit from a DPC or direct integrative care membership. But for the day-to-day work of staying healthy, managing chronic conditions, and addressing health concerns before they become crises? Direct care offers something the traditional system simply cannot: a relationship with your physician that isn't mediated by billing codes and insurance company gatekeepers. As you navigate the difficult decisions ahead regarding your 2026 coverage, I encourage you to think beyond the traditional options. The direct care movement is growing because it works—for clients who want genuine relationships with their healthcare providers, and for physicians who went into medicine to heal people, not to spend their days fighting with insurance companies. The 2026 healthcare cost crisis is real, and for many families, it will be painful. But within that crisis lies an opportunity to ask bigger questions about what we really want from our healthcare system—and to discover alternatives that may serve us far better than the broken model we've been handed. — — — References and Resources Data Sources and Policy Analysis Kaiser Family Foundation (KFF). "ACA Marketplace Premium Payments Would More Than Double on Average Next Year if Enhanced Premium Tax Credits Expire." January 21, 2026. https://www.kff.org/affordable-care-act/aca-marketplace-premium-payments-would-more-than-double-on-average-next-year-if-enhanced-premium-tax-credits-expire/ Kaiser Family Foundation (KFF). "What We Know So Far About 2026 ACA Marketplace Enrollment, Premiums, and Deductibles." July 2026. https://www.kff.org/affordable-care-act/what-we-know-so-far-about-2026-aca-marketplace-enrollment-premiums-and-deductibles/ Kaiser Family Foundation (KFF). "How Much and Why Premiums Are Going Up for Small Businesses in 2026." September 2025. https://www.kff.org/health-costs/how-much-and-why-premiums-are-going-up-for-small-businesses-in-2026/ Urban Institute. "4.8 Million People Will Lose Coverage in 2026 If Enhanced Premium Tax Credits Expire." December 2025. https://www.urban.org/research/publication/48-million-people-will-lose-coverage-2026-if-enhanced-premium-tax-credits Commonwealth Fund. "Expiring Premium Tax Credits Lead to State Job Losses in 2026." October 2025. https://www.commonwealthfund.org/publications/issue-briefs/2025/oct/expiring-premium-tax-credits-lead-340000-jobs-lost-2026 Families USA. "Why Health Insurance Premiums Continue to Skyrocket." November 2025. https://familiesusa.org/resources/why-health-insurance-premiums-continue-to-skyrocket/ Families USA. "Another Year of Double-Digit Rate Increases? 2027 Proposed Insurance Premiums Tracker." July 2026. https://familiesusa.org/press-releases/another-year-of-double-digit-rate-increases-families-usa-launches-live-tracker-for-2027-proposed-insurance-premiums/ Mercer. "Employers Prepare for the Highest Health Benefit Cost Increase in 15 Years." September 2025. https://www.mercer.com/en-us/insights/us-health-news/employers-prepare-for-the-highest-health-benefit-cost-increase-in-15-years/ Mercer. "US Employers and Workers Will Face Affordability Crunch as Health Insurance Cost Is Expected to Exceed $18,500 per Employee in 2026." November 2025. https://www.mercer.com/en-us/about/newsroom/employers-and-workers-face-affordability-crunch-as-health-insurnace-cost-is-expected-to-exceed-18500-per-employee-in-2026/ Congressional Research Service. "Enhanced Premium Tax Credit and 2026 Exchange Premiums: Frequently Asked Questions." 2025. https://www.congress.gov/crs-product/R48290 AJMC (American Journal of Managed Care). "5 Consequences If ACA Premium Subsidies End in 2026." July 2026. https://www.ajmc.com/view/5-consequences-if-aca-premium-subsidies-end-in-2026 Fidelity Investments. "What to Do After ACA Premiums Go Up." February 2026. https://www.fidelity.com/learning-center/personal-finance/reduce-health-care-costs-aca-subsidies Texas-Specific Sources Baker Institute, Rice University. "Emerging Trends in Texas ACA Marketplace Enrollment for 2026." April 2026. https://www.bakerinstitute.org/research/emerging-trends-texas-aca-marketplace-enrollment-2026 Texas Tribune. "Texas Health Insurance Premiums: ACA Tax Credit Expiration." August 2025. https://www.texastribune.org/2025/08/21/texas-health-insurance-premiums-aca-tax-credit-expiration Texas 2036. "Texas ACA Enrollment Hits Record High in 2026, Surpassing Last Year." January 2026. https://texas2036.org/posts/texas-aca-enrollment-hits-record-high-in-2026-surpassing-last-year/ Texas 2036. "What to Expect in 2026 ACA Marketplace: A Changing Landscape." December 2025. https://texas2036.org/news-analysis/what-to-expect-in-2026-aca-marketplace-a-changing-landscape/ Axios Dallas. "Texas Sees More Enrolled in Affordable Care Act Insurance." February 2026. https://www.axios.com/local/dallas/2026/02/04/texas-sees-more-enrolled-in-affordable-care-act-insurance Texas Tribune. "Texas' ACA Enrollment Shrinks by 4% After Tax Credit Expiration." July 2026. https://www.texastribune.org/2026/07/09/texas-aca-obamacare-health-insurance-effectuation/ ACA Signups. "2026 Final Gross Rate Changes - Texas." November 2025. https://acasignups.net/rate_changes/2026/tx Texas Medical Association. "Federal Changes Allow Payment for Direct Primary Care Via Health Savings Accounts." September 2025. https://www.texmed.org/Template.aspx?id=66742 Employer Health Cost Sources SHRM. "Employers Brace for 15-Year-High Health Benefit Cost Hike." September 2025. https://www.shrm.org/topics-tools/news/benefits-compensation/employers-brace-15-year-high-health-benefit-cost-hike Fierce Healthcare. "Employers Brace for 6.7% Increase in Health Benefits Costs Next Year: Mercer." November 2025. https://www.fiercehealthcare.com/payers/employers-brace-67-increase-health-benefits-costs-next-year-mercer Healthcare Finance News. "Employers Anticipate 6.7% Jump in Health Benefits Costs, Finds Mercer." November 2025. https://www.healthcarefinancenews.com/news/employers-anticipate-67-jump-health-benefits-costs-finds-mercer Peterson-KFF Health System Tracker. "How Much and Why Premiums Are Going Up for Small Businesses in 2026." September 2025. https://www.healthsystemtracker.org/brief/how-much-and-why-premiums-are-going-up-for-small-businesses-in-2026/ Direct Primary Care Organizations and Data Hint Health. "2026 Direct Primary Care Trends Report (Press Release via PR Newswire)." April 23, 2026. https://www.prnewswire.com/news-releases/hint-health-releases-2026-direct-primary-care-trends-report-data-shows-dpc-has-moved-from-niche-alternative-to-national-healthcare-infrastructure-302751249.html Hint Health Blog. "State of DPC 2026: Key Takeaways From DPC Alliance's Physician Survey." July 2026. https://blog.hint.com/state-of-dpc-2026-key-takeaways-from-the-dpc-alliances-physician-survey Hint Health Blog. "The Data Behind DPC's Next Phase of Growth." May 2026. https://blog.hint.com/the-data-behind-dpc DPC Alliance (DPCA). "State of Direct Primary Care 2026 Report." July 2026. https://assets.noviams.com/novi-file-uploads/dpca/pdfs-and-documents/State_of_DPC_FINAL2026.pdf DPC Frontier Find a DPC practice near you. Interactive mapper and state-by-state DPC law tracker. dpcfrontier.com Direct Primary Care Coalition (DPCC) Advocacy organization supporting state, federal, and private sector policies that advance DPC. dpcare.org Direct Primary Care Alliance (DPCA) Physician-led organization providing education, mentorship, and advocacy for the DPC community. dpcalliance.org Patient Options Comprehensive state-by-state guide to DPC practice laws (2026 edition). patientoptions.org/dpc-laws-by-state/ HSA and DPC Legislation Hint Health Blog. "Expanding Access to Direct Primary Care: How the One Big Beautiful Bill Changes the Game." March 2026. https://blog.hint.com/expanding-access-to-direct-primary-care-how-the-one-big-beautiful-bill-changes-the-game Salta Direct. "HSA + Direct Primary Care: What the One Big Beautiful Bill Means for Patients and Employers in 2026." April 2026. https://saltadirect.com/hsa-direct-primary-care-what-the-one-big-beautiful-bill-means-for-patients-and-employers-in-2026/ Lively. "2026 HSA Eligibility, Coverage, and OBBB Changes." 2026. https://livelyme.com/guides/obbb-hsa-guide McDermott Will & Emery. "Direct Primary Care Arrangements 50-State Survey." June 2024. https://www.mcdermottlaw.com/resources/direct-primary-care-arrangements-50-state-survey/ Transparent Pricing Services Surgery Center of Oklahoma Pioneer in transparent, all-inclusive surgical pricing. Complete prices published online for every procedure. surgerycenterok.com Green Imaging Affordable direct-pay MRIs, CT scans, ultrasounds, and other imaging. Network of 4,500+ facilities nationwide. greenimaging.net Direct Specialty Care Direct Specialty Care Alliance (DSC Alliance) Organization leading the movement of specialist physicians providing direct care services. Founded by Dr. Diana Girnita. dscalliance.org Health Sharing Communities Sedera Medical cost sharing community founded in 2014 in Austin, Texas. Secular (no religious requirement). Individual plans starting at approximately $153/month (2026 rates). sedera.com HealthShare Guide Independent comparison resource for evaluating health sharing organizations. healthshareguide.org Direct Integrative Care Direct Integrative Care Membership-based integrative and functional medicine practice founded by Yoon Hang "John" Kim, MD, MPH, offering telemedicine services across multiple states with wholesale lab pricing and supplement discounts. www.directintegrativecare.com Additional News Coverage and Analysis Advisory Board. "Health Policy Roundup: ACA Premiums Skyrocket After Enhanced Subsidies Expire." January 7, 2026. https://www.advisory.com/daily-briefing/2026/01/07/health-policy-roundup The Century Foundation. "It's Official: Americans Will Pay Much More for All Types of Health Coverage in 2026." February 2026. https://tcf.org/content/commentary/its-official-americans-will-pay-much-more-for-all-types-of-health-coverage-in-2026-including-medicare/ Oxfam America / Human Rights Watch. "US: Millions Face Soaring Health Costs as Subsidies Expire." 2025. https://www.oxfamamerica.org/press/us-millions-face-soaring-health-costs-as-subsidies-expire/ Medical Daily. "4.8 Million Americans Have Lost Health Insurance After ACA Subsidies Expired, Urban Institute Confirms." July 2026. https://www.medicaldaily.com/aca-subsidies-expired-2026-4-million-uninsured-urban-institute-476153 BestDPC. "State of Direct Primary Care 2026: Clinics by State and City Data." July 2026. https://bestdpc.com/state-of-direct-primary-care-2026/ — — — About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, along with UCLA medical acupuncture certification. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of three books and over 20 peer-reviewed articles, and he founded and moderates the LDN Support Group—a community of over 9,000 members. Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com Medical Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented reflects general principles of integrative and functional medicine and is not intended as a substitute for individualized care from a qualified healthcare provider. Always consult with your physician before starting, modifying, or discontinuing any treatment. Last updated: August 2026 Medically reviewed by: Yoon Hang Kim, MD, MPH — Board-Certified in Preventive Medicine What Is Functional Medicine — and Why Does It Matter for Chronic Conditions? If you are living with a chronic health condition — fatigue that does not resolve with rest, persistent pain, autoimmune flares, digestive dysfunction, brain fog, or symptoms that have eluded a clear diagnosis — you have probably experienced the limits of a symptom-first approach. You receive a prescription for what hurts, an antibiotic for what is inflamed, or a reassurance that test results are "normal" even though you do not feel normal. Functional medicine takes a fundamentally different approach. Rather than asking what medication matches this symptom, it asks why is this symptom happening in this particular person. The goal is to identify and address the upstream drivers of illness — the root causes — rather than managing downstream effects indefinitely. This distinction is not philosophical. It changes what gets tested, what gets treated, and how long the practitioner spends understanding your history. In functional medicine, the initial evaluation often takes 60 to 90 minutes because the clinical picture that matters is the full picture: genetics, environment, nutrition, sleep architecture, stress physiology, toxic exposures, gut integrity, hormonal balance, and how all of these interact in your specific body. How Does Functional Medicine Differ from Conventional Care? Conventional medicine excels at acute illness, emergencies, surgical intervention, and well-defined infectious disease. For these situations, the diagnostic-and-prescribe model is exactly what is needed, and it saves lives every day. Where conventional care often struggles is with the complex, multisystem, chronic conditions that now account for the majority of healthcare spending and patient suffering in the United States. Conditions like autoimmune disease, chronic fatigue, fibromyalgia, mast cell activation syndrome (MCAS), irritable bowel syndrome, and chronic pain frequently involve dysfunction across multiple organ systems simultaneously. Treating each symptom in isolation — a gastroenterologist for the gut, a rheumatologist for the joints, a neurologist for the headaches — can produce a medication list without producing improvement. Functional medicine treats the body as an interconnected system. Digestive dysfunction, for example, does not stay confined to the gut. It can drive systemic inflammation, alter neurotransmitter production, disrupt hormonal balance, and impair immune regulation. Addressing the gut may improve mood, energy, skin, and joint pain — not because the gut is a magic organ, but because the underlying biology is genuinely connected. The published literature increasingly supports this systems-level framework: intestinal permeability and microbial dysbiosis have been linked to autoimmune activation, neuroinflammation, and metabolic disruption across dozens of well-designed studies (Fasano, 2020; Clemente et al., 2018). This approach requires time, partnership, and a willingness — from both clinician and patient — to look beyond the obvious. It is not faster than conventional care. It is often slower, more detailed, and more demanding. But for the right conditions, it produces results that symptom management alone cannot. Why Does This Matter Especially for Patients in San Antonio? San Antonio is the seventh-largest city in the United States, with a diverse population that carries a disproportionate burden of chronic metabolic and autoimmune disease. Texas ranks among the highest states for prevalence of type 2 diabetes, obesity, and autoimmune conditions — many of which have root-cause drivers that are addressable through the functional medicine framework: nutritional insufficiency, environmental exposures, chronic stress, gut dysbiosis, and inflammatory diet patterns. Despite this need, access to physicians trained in both conventional and functional medicine remains limited in much of Texas. Most primary care visits in the state last 15 minutes or fewer — a time frame that is simply inadequate for the kind of complex, multisystem evaluation that chronic illness demands. Direct Integrative Care was established to address this gap. The practice model is built around unhurried consultations, comprehensive laboratory evaluation, and a treatment philosophy that integrates evidence-based conventional medicine with functional medicine principles — without abandoning the rigor that sound clinical practice requires. Who Is Dr. Yoon Hang Kim? Dr. Yoon Hang "John" Kim has been practicing integrative and functional medicine since 1999 — over 25 years of clinical experience focused specifically on the intersection of conventional medicine, evidence-based complementary therapies, and root-cause resolution for complex chronic illness. His training and credentials reflect a career built deliberately around this intersection: Board Certification in Preventive Medicine — conferred by the American Board of Preventive Medicine. This is one of 24 medical specialties recognized by the American Board of Medical Specialties (ABMS) and is focused on disease prevention, health promotion, and population-level health strategy. It is a distinct board certification, not a continuing education certificate. Residential Fellowship under Dr. Andrew Weil — Dr. Kim completed the Integrative Medicine Fellowship at the University of Arizona's Andrew Weil Center for Integrative Medicine as an Osher Fellow. This is the oldest and most widely recognized university-based integrative medicine fellowship in the world, and Dr. Weil is broadly regarded as the founder of the academic integrative medicine movement. The fellowship is a rigorous, 1,000-hour clinical training program — not a weekend seminar. Institute for Functional Medicine (IFM) Scholar — Dr. Kim was named a recipient of the 2024 Functional Medicine for All Scholarship, awarded by the Institute for Functional Medicine to physicians committed to bringing functional medicine to underserved and rural populations. This reflects IFM's recognition of Dr. Kim's clinical work and commitment to expanding access to root-cause medicine. Additional Certifications and Training: Master of Public Health (MPH), San Diego State University Medical Degree, Medical College of Wisconsin (Class of 1997) American Board of Medical Acupuncture (UCLA Medical Acupuncture Training Program) American Board of Integrative and Holistic Medicine Howard Hughes Research Fellowship in Pharmacology Leadership and Academic Positions: Former Medical Director, Integrative Oncology Program, Miami Cancer Institute at Baptist Health South Florida Former Director, University of Kansas Medical Center Integrative Medicine Program Founder, Integrative Health Studies Certificate Program, University of West Georgia Former Chief Wellness Officer, Memorial Hospital Publications: Dr. Kim is the author of three books — including the LDN Primer and a clinical LDN textbook — and more than 20 peer-reviewed articles in integrative medicine. These credentials matter for a specific reason. Under Google's YMYL (Your Money or Your Life) quality guidelines, health content is held to the highest standard of expertise and trustworthiness. The difference between health information written by someone with genuine clinical authority and health information written by a content marketer is not just an SEO consideration — it is a patient safety consideration. Dr. Kim's content on this site and on the companion clinical blog at ifmsynergy.com reflects over two decades of direct clinical experience, not secondhand summaries of other people's work. What Conditions Does Functional Medicine Address? Functional medicine is not a replacement for all of conventional medicine. It is a framework that is particularly well-suited to conditions where root-cause complexity outstrips the capacity of a single-system, single-drug approach. The conditions Dr. Kim most commonly evaluates and manages include: Autoimmune Conditions — including Hashimoto's thyroiditis, rheumatoid arthritis, lupus, psoriasis, multiple sclerosis, and inflammatory bowel disease (Crohn's disease and ulcerative colitis). The functional medicine approach to autoimmunity focuses on identifying the triggers — gut permeability, molecular mimicry, environmental toxicants, chronic infection, and nutritional insufficiency — that drive immune dysregulation. Chronic Pain and Fibromyalgia — conditions characterized by central sensitization, neuroinflammation, and dysfunction of the body's pain-modulating systems. Conventional pain management often relies on medications that mask symptoms without addressing the underlying neuroinflammatory or neuroimmune drivers. Functional medicine evaluation may identify contributing factors such as small intestinal bacterial overgrowth (SIBO), mold exposure, nutrient depletion, or hormonal imbalance. Chronic Fatigue Syndrome (ME/CFS) and Long COVID — complex neuroimmune conditions that involve mitochondrial dysfunction, immune dysregulation, autonomic dysfunction, and post-exertional malaise. These conditions require careful clinical management that respects the patient's energy limitations while systematically addressing identifiable contributors. Mast Cell Activation Syndrome (MCAS) — a condition involving inappropriate activation of mast cells, leading to multisystem symptoms including flushing, gastrointestinal distress, brain fog, tachycardia, and histamine intolerance. MCAS is frequently underdiagnosed and often overlaps with ME/CFS, dysautonomia, and connective tissue disorders. Hormonal Imbalances — including thyroid dysfunction, adrenal stress patterns, sex hormone imbalances, and metabolic syndrome. Digestive Disorders — including SIBO, irritable bowel syndrome, inflammatory bowel disease, and food sensitivities. Mold-Related Illness — chronic inflammatory response syndrome (CIRS) and mycotoxin-related health effects. What Is Low Dose Naltrexone (LDN) — and Why Is It Relevant to Functional Medicine? One of the most clinically significant tools in integrative medicine for complex chronic conditions is low dose naltrexone (LDN). This is an area of particular depth and focus in Dr. Kim's practice — and it illustrates why practitioner expertise matters so much in functional medicine. Naltrexone is an FDA-approved medication used at standard doses (50 mg) to treat opioid and alcohol use disorders. At low doses — typically 0.5 mg to 4.5 mg — it appears to work through a fundamentally different set of mechanisms: modulating glial cell activity and Toll-like receptor 4 (TLR4) signaling in the central nervous system, reducing neuroinflammation, and potentially supporting endogenous opioid tone through a brief, transient blockade of opioid receptors followed by a compensatory upregulation (Younger et al., 2014; PMID: 24526250). The published evidence for LDN spans multiple conditions. Small controlled trials have demonstrated benefit in Crohn's disease (Smith et al., 2007; PMID: 17222320; Smith et al., 2011; PMID: 21380937). Pilot and crossover studies have shown signals of benefit in fibromyalgia (Younger et al., 2009; PMID: 19453963; Younger et al., 2013; PMID: 23359310), though the largest randomized trial to date — 99 women receiving 6 mg naltrexone vs. placebo — did not find LDN superior to placebo for its primary pain outcome (Due Bruun et al., 2024; PMID: 38258677). In multiple sclerosis, a pilot trial showed improvement in mental-health quality of life (Cree et al., 2010; PMID: 20695007). A 2026 systematic review and meta-analysis in BMJ Open found moderate-to-large favorable effect sizes for fatigue, pain, and sleep in long COVID and ME/CFS — while explicitly rating overall certainty of evidence as low and noting that no randomized controlled trials were identified (Byambasuren et al., 2026). Why practitioner expertise matters for LDN: LDN is not a simple prescription. Dosing is highly individualized. Some patients — particularly those with MCAS, ME/CFS, or heightened neurological sensitivity — respond to microgram-level doses and cannot tolerate standard titration protocols. Rapid dose escalation is one of the most common causes of avoidable side effects. The timing of doses, the formulation (immediate-release vs. compounded), the interaction with other medications (particularly opioids — a genuine safety issue requiring perioperative planning), and the integration of LDN into a broader functional medicine treatment plan all require clinical judgment that comes from sustained, focused experience. Dr. Kim leads the LDN Support Group, a community of over 9,000 members, and is the author of the LDN Primer and a clinical LDN textbook. His clinical work with LDN is documented extensively at ifmsynergy.com, and his approach to LDN therapy is described in detail at Best Doctor for LDN Therapy. What Should You Expect in a Functional Medicine Evaluation? A first visit with Dr. Kim typically involves an extended consultation — far longer than a conventional office visit — focused on building a comprehensive understanding of your clinical picture. Detailed Health History — This includes not just your current symptoms and medication list, but your full medical timeline: childhood illnesses, environmental exposures, dietary patterns, sleep quality, stress history, family history, and the chronological sequence in which your symptoms developed. The timeline often reveals connections that are invisible when symptoms are treated as isolated events. Advanced Laboratory Testing — Functional medicine often uses laboratory panels that go beyond standard bloodwork. Depending on the clinical picture, this may include comprehensive thyroid panels (not just TSH), advanced lipid markers (such as NMR LDL particle number or ApoB/ApoA-I ratio), inflammatory markers (hs-CRP, cytokine panels), gut microbiome analysis, organic acids testing, nutrient levels, hormone panels, mold and mycotoxin testing, or food sensitivity panels. The goal is to identify the measurable upstream drivers, not just confirm or rule out a named diagnosis. Individualized Treatment Plan — Based on the history and laboratory findings, a plan is developed that may include nutritional optimization, targeted supplementation, stress and sleep interventions, pharmaceutical therapy where indicated (including LDN for appropriate candidates), medical acupuncture, detoxification support, and lifestyle modification. The plan is iterative — it evolves as your body responds and as follow-up testing reveals changes. Ongoing Partnership — Functional medicine is not a one-visit solution. Complex chronic conditions require ongoing monitoring, titration, and adjustment. Dr. Kim's practice model is built around this reality, with regular follow-up and accessible communication. How Is Direct Integrative Care Structured? Direct Integrative Care uses a membership-based direct care model. This means the practice operates independently of insurance-driven time constraints — allowing for the unhurried, comprehensive consultations that functional medicine requires. The practice serves patients both in San Antonio and through telemedicine across multiple states, including Texas, Florida, Georgia, Illinois, Iowa, and Missouri. This expanded access is particularly important because many patients with complex chronic conditions — especially ME/CFS, MCAS, and Long COVID — have difficulty finding practitioners with specialized expertise locally. To begin the process: Virtual Assessment Form: Complete the form here Secure Contact: Contact Direct Integrative Care Phone/Text: (210) 981-6106 Frequently Asked Questions Is functional medicine evidence-based? Yes — with an important nuance. Functional medicine draws on the same peer-reviewed biomedical literature as conventional medicine. The difference is in the clinical framework: functional medicine organizes that evidence around root-cause identification and systems biology rather than diagnosis-and-prescribe. Some interventions used in functional medicine have robust clinical trial support; others are supported by mechanistic evidence and clinical experience while larger trials are still underway. A responsible functional medicine physician — as with any good clinician — is transparent about the strength of evidence behind each recommendation. Does Dr. Kim still practice conventional medicine? Yes. Dr. Kim is a board-certified physician who is fully trained in conventional medicine. Integrative and functional medicine is not a rejection of conventional care — it is an expansion of it. When a conventional pharmaceutical is the best tool for a given situation, it is used. The goal is to have the broadest possible toolkit and to select the approach that addresses the root cause most effectively. Can I see Dr. Kim if I do not live in San Antonio? In most cases, yes. Integative & Functional Medicine Practice of Yoon Hang Kim MD offers telemedicine consultations across multiple states. Many patients with complex chronic conditions — particularly those exploring LDN therapy, MCAS management, or ME/CFS evaluation — work with Dr. Kim remotely. What is the difference between integrative medicine and functional medicine? These terms overlap significantly but are not identical. Integrative medicine combines conventional medical treatments with evidence-based complementary therapies (such as acupuncture, nutritional medicine, and mind-body practices). Functional medicine is a clinical framework focused on identifying and treating root causes of disease through a systems biology approach. Dr. Kim's training and practice incorporate both — the therapeutic breadth of integrative medicine and the diagnostic depth of functional medicine. Is LDN appropriate for everyone with a chronic condition? No. LDN is a tool — sometimes a powerful one — but it is not universally appropriate. It requires careful patient selection, individualized dosing, and integration into a broader treatment plan. Some patients cannot tolerate LDN at any dose. The decision to use LDN should be made in partnership with a clinician who has specific expertise in its prescribing and management. Dr. Kim's approach to LDN is described in detail at ifmsynergy.com. Summary Topic Key Point What is functional medicine? A clinical approach that identifies and addresses root causes of chronic illness rather than managing symptoms in isolation Who is Dr. Yoon Hang Kim? Board-certified preventive medicine physician with 25+ years of integrative and functional medicine experience; Andrew Weil Fellow; IFM Scholar; author of 3 books and 20+ peer-reviewed articles What conditions are addressed? Autoimmune disease, chronic pain, fibromyalgia, ME/CFS, Long COVID, MCAS, hormonal imbalance, digestive disorders, mold illness What is LDN? Low dose naltrexone — a repurposed medication used at low doses for neuroinflammation and immune modulation; an area of particular clinical expertise for Dr. Kim How is care delivered? Membership-based direct care model with extended consultations; available in-person (San Antonio) and via telemedicine across multiple states How do I start? Complete the Virtual Assessment Form or call/text (210) 981-6106 #FunctionalMedicine #IntegrativeMedicine #SanAntonioDoctor #RootCauseMedicine #LDN #LowDoseNaltrexone #ChronicPain #Autoimmune #MECFS #LongCOVID #MCAS #FibromyalgiaTreatment #PersonalizedMedicine #PreventiveMedicine #DrKim #DirectIntegrativeCare #TelemedicineTX #FunctionalMedicineSanAntonio #IntegrativeMedicineSanAntonio #HolisticHealth Related Reading Best Doctor for Low Dose Naltrexone (LDN) Therapy — Direct Integrative Care 15 Teaching Points from the LDN Support Group Pop-Up Live — An Evidence-Referenced Review — ifmsynergy.com Endorphins: Biochemistry, Bioregulation, and Clinical Levers — ifmsynergy.com Pharmacogenomics and Naltrexone: Can Your Genes Predict How You Respond? — ifmsynergy.com Low-Dose Naltrexone (LDN) as an Adjunct in PANS/PANDAS — ifmsynergy.com Navigating Supplement and Medication Sequencing in ME/CFS-MCAS Overlap — ifmsynergy.com About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician in Preventive Medicine with over 25 years of clinical experience in integrative and functional medicine. He completed a residential fellowship as an Osher Fellow at the University of Arizona's Andrew Weil Center for Integrative Medicine and holds additional certifications in medical acupuncture (UCLA) and integrative and holistic medicine. Dr. Kim is an IFM Scholar and recipient of the 2024 Functional Medicine for All Scholarship from the Institute for Functional Medicine. He was also awarded the Howard Hughes Research Fellowship in Pharmacology. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome (ME/CFS), mast cell activation syndrome (MCAS), and mold-related illness. He is the author of 3 books — including the LDN Primer and a clinical LDN textbook — and more than 20 peer-reviewed articles. He leads the LDN Support Group, a community of over 9,000 members. He has served as Medical Director of the Integrative Oncology Program at Miami Cancer Institute and Director of the University of Kansas Medical Center Integrative Medicine Program. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com | Blog: www.ifmsynergy.com References Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250 Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x. PMID: 19453963 Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734. PMID: 23359310 Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820–828. doi:10.1111/j.1572-0241.2007.01045.x. PMID: 17222320 Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56(7):2088–2097. doi:10.1007/s10620-011-1653-7. PMID: 21380937 Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145–150. doi:10.1002/ana.22006. PMID: 20695007 Due Bruun K, Christensen R, Amris K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024;6(1):e31–e39. doi:10.1016/S2665-9913(23)00278-3. PMID: 38258677 Byambasuren O, Atkins TJ, Baptista S, Glasziou P, Chakraborty S. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ Open. 2026;16:e111253. doi:10.1136/bmjopen-2025-111253. (Institute for Evidence-Based Healthcare, Bond University; certainty of evidence rated low by the authors.) Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9:F1000 Faculty Rev-69. doi:10.12688/f1000research.20510.1. PMID: 32051759 Clemente JC, Manasson J, Scher JU. The role of the gut microbiome in systemic inflammatory disease. BMJ. 2018;360:j5145. doi:10.1136/bmj.j5145. PMID: 29311119 Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016. PMC5489802 All references were verified against PubMed or publisher records. Citations reflect the strength and limitations of the underlying evidence, including trials with negative as well as positive results.

How membership-based integrative and functional medicine works — and whether it's right for you Written and medically reviewed by Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Based in San Antonio, Texas · Virtual practice serving TX, IA, IL, MO, FL, and GA www.directintegrativecare.com Last updated: August 2026 Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, financial advice, tax advice, or a recommendation to discontinue health insurance coverage. Direct Care is not health insurance. Consult a qualified healthcare professional regarding your medical care and a qualified advisor regarding financial or tax decisions. What Is Direct Care, in One Paragraph? Direct Care is a membership model in which you pay your physician a flat monthly fee instead of routing every visit through insurance. That fee covers unhurried appointments, direct phone and text access, and ongoing care — with no copays and no billing surprises. It is not insurance, and it does not replace it: most members keep a high-deductible plan for hospitalization and emergencies. The trade is straightforward. Your physician carries a much smaller patient panel — roughly 400 patients in the average Direct Primary Care practice, versus 2,000 to 2,500 in a traditional one — and in exchange has the time to actually practice medicine. For integrative and functional medicine specifically, that time is not a luxury. It is the entire point. Root-cause work requires the kind of long, iterative conversations that a seven-minute insurance visit structurally cannot accommodate. Why Is Traditional Medicine So Rushed? The answer is billing, not indifference. In insurance-based practices, the office visit is the unit of transaction. Insurers pay for encounters. Phone consultations are generally not covered. Text messages to your doctor are not covered. A quick email that might save you an unnecessary appointment is not a billable event. This creates a perverse incentive. Every minute a physician spends answering your question by phone is a minute not generating revenue. The result is schedules packed with 20 to 30 or more patients per day, because that is what keeps the lights on and the staff paid. The math behind this is worse than most patients realize. Research published in the Journal of General Internal Medicine (Porter et al., 2022) estimated that a primary care physician would need 26.7 hours per day to deliver all guideline-recommended preventive, chronic, and acute care — plus documentation — for a standard panel of 2,500 patients. There are not that many hours in a day. Something has to give, and what gives is time with you. What Is Driving Patients and Physicians Toward This Model? Cost. The Kaiser Family Foundation's 2025 Employer Health Benefits Survey found that total annual premiums for employer-sponsored family coverage reached $26,993, with workers contributing an average of $6,850 from their paychecks. Mercer's 2025 survey projects health benefit costs per employee will rise 6.5% in 2026 — the steepest increase since 2010, and closer to 9% without employer cost-cutting. Many families now pay thousands out of pocket before a deductible is met. Physician burnout. The 2025 Commonwealth Fund International Health Policy Survey found that 43% of U.S. primary care physicians report burnout — the highest of ten developed countries surveyed. Among them, 44% cite administrative tasks as the primary driver and 65% say insurance-related paperwork is a major problem. A 2022 analysis in Mayo Clinic Proceedings estimated that burnout-related primary care turnover costs the system $260 million annually in excess healthcare spending. When the incentives punish both parties, people look for a different arrangement. How Does a Direct Care Membership Actually Work? In exchange for a flat monthly fee, members receive access that insurance-based practices structurally cannot offer: Unhurried appointments — 30 to 60 minutes, rather than the standard 5 to 10 Direct access — phone, text, email, and telemedicine, not just scheduled office visits Expanded availability — including evenings and weekends Smaller panels — the AAFP's 2024 DPC Data Brief puts the average Direct Primary Care panel at 402 patients Transparent pricing — one monthly fee, no copays, no surprise bills Your first appointment is typically an extended intake: full health history, current concerns, goals, and often lab work — the foundation for a personalized plan rather than a symptom-by-symptom triage. The model has scaled considerably. The DPC Coalition reports more than 2,300 DPC practices serving over 300,000 patients, while the DPC Frontier mapper now lists over 3,100 practice locations nationwide. Thirty-four states have passed laws defining DPC as a medical service rather than insurance. Why Is Direct Care a Natural Fit for Integrative and Functional Medicine? Because root-cause medicine is time-intensive, and insurance does not pay for time. Instead of prescribing something for each symptom and moving on, functional medicine asks why. Why is the blood pressure elevated? Why the persistent fatigue? What in your sleep, stress, nutrition, environment, or history is contributing? That detective work cannot be compressed into a rushed visit. Insurance reimbursement has always been poor for exactly these approaches: extended consultations, advanced functional testing, many integrative procedures. Supplements receive no coverage at all. For patients accustomed to paying à la carte every time a physician's time was involved, the membership model consolidates all of it into one predictable fee. This matters most for the conditions that don't fit neatly into conventional categories — autoimmune disease, chronic fatigue, fibromyalgia, MCAS, mold toxicity, long COVID, and the frustrating experience of being told "your labs are normal" while clearly not feeling well. These are precisely the cases that require time, sequencing, and iteration. In my own practice, I have capped my panel at 99 patients. That is smaller than the DPC average, and deliberately so. Complex, sensitive patients require a level of responsiveness that a larger panel cannot honestly support. What Does the Evidence Actually Show? Honestly: encouraging, but not definitive. A 2020 Society of Actuaries report prepared by Milliman found that patients enrolled in a DPC option used fewer downstream services, driven mainly by lower emergency department utilization — while also noting that an employer's net costs depend heavily on how the total benefits package is structured. Several employer-sponsored evaluations have reported reductions in ED visits and hospitalizations. The caveat matters: most of this evidence is observational and drawn from employer-sponsored populations, not randomized trials. Critics reasonably note that healthier patients may self-select into these practices. I think the model is sound and my patients do better under it, but I would rather tell you what the literature supports than oversell it. Is Direct Care Right for You? It tends to be a strong fit if you: Manage a chronic or complex condition requiring ongoing adjustment Have a high-deductible plan and are already paying out of pocket for primary care Want integrative or functional medicine and are tired of paying per visit Value access and continuity over having insurance process every transaction Have felt dismissed or rushed in conventional settings It may not be the right fit if you rarely use healthcare and are satisfied with your current arrangement, if a monthly fee on top of insurance premiums is not affordable, or if you need a physician who bills your insurance directly. Direct Care Is Not Insurance — This Part Matters Direct Care complements insurance; it does not replace it. Catastrophic coverage remains essential for hospitalization, surgery, cancer treatment, and serious accidents. Most members pair their membership with a high-deductible health plan, which typically carries a lower premium while protecting against major expenses. A note on Medicare. This is frequently misunderstood. Medicare beneficiaries can join most Direct Care practices. The complication sits on the physician's side: most DPC physicians formally opt out of Medicare, which means Medicare will not reimburse for that physician's services. Your Medicare coverage continues normally for everything else — hospitalizations, imaging, labs, specialists, and prescriptions. Medicare will not pay the membership fee itself. If you are on Medicare, ask any practice directly how they are structured before enrolling. Can I Use My HSA for a Direct Care Membership in 2026? Yes — this is new, and it is significant. Under the One Big Beautiful Bill Act (H.R. 1), signed July 4, 2025 and effective January 1, 2026, Direct Primary Care membership fees are recognized as qualified medical expenses under HSA rules. Pre-tax HSA funds may be used up to $150 per month for individuals and $300 per month for families. Just as importantly, a qualifying DPC arrangement no longer counts as disqualifying "other coverage," so pairing a membership with an HSA-eligible high-deductible plan no longer jeopardizes your ability to contribute. Consult your tax advisor about your specific situation. Summary: Direct Care at a Glance Traditional Insurance-Based Care Direct Care Membership Payment Fee-for-service billed to insurer Flat monthly fee paid to physician Typical panel size 2,000–2,500 patients ~400 patients (99 in my practice) Visit length 5–15 minutes 30–60 minutes Access between visits Limited; often not billable Phone, text, email, telemedicine Copays / surprise bills Common None for included services Functional medicine testing Spotty or no coverage Discussed openly; transparent pricing Replaces insurance? — No — pair with catastrophic/HDHP HSA-eligible (2026) — Yes, up to $150/mo individual, $300/mo family Frequently Asked Questions Is Direct Care the same as concierge medicine? No. Concierge practices typically still bill insurance and charge an additional retainer, often a substantially higher one. Direct Care practices generally do not bill insurance at all, and fees are lower. Do I still need health insurance? Yes. Direct Care covers primary and ongoing care, not hospitalization, surgery, or catastrophic events. Most members pair membership with a high-deductible plan. What if I need a specialist or hospital care? Your physician coordinates referrals and works with the specialist. Your insurance covers those services as it normally would. Direct Specialty Care practices are also an emerging option for insurance-free specialist access. Can I use HSA funds? Yes, as of January 1, 2026, up to $150/month individual or $300/month family. Can Medicare patients join? Generally yes, though Medicare will not reimburse an opted-out physician's services or the membership fee. Ask each practice how they are structured. How do I find a Direct Care practice near me? Search the DPC Frontier mapper or DPC Nation. For specialists, use the DSC Alliance directory. For Physicians: Resources for Starting Your Own Direct Care Practice If you are a physician considering the transition, the movement is far better supported than it was even five years ago. These are the organizations I recommend: DPC Frontier — The essential legal and regulatory resource. Their state-by-state guides cover defining legislation and insurance-law considerations, and their guidance on opting out of Medicare is required reading before you structure your practice. Direct Primary Care Alliance (DPCA) — The national 501(c)(6) focused solely on DPC physicians: education, mentorship, masterminds, group purchasing, and malpractice discounts. See membership benefits. Direct Specialty Care Alliance (DSC Alliance) — Founded in 2020 for specialists building insurance-free practices. Contracts, templates, and a structured starter course built for the specific challenges specialists face. DPC Coalition (DPCC) — The leading policy and advocacy organization, and the group behind the HSA legislative win. Free Market Medical Association (FMMA) — Broader price-transparency movement connecting physicians, patients, and self-funded employers. The San Antonio chapter is worth knowing for Texas physicians. DPC Nation — Patient-facing community and Facebook group. I have written a practical, unglamorous guide to the startup process — costs, entity formation, SEO, and the mistakes I made — here: So Doctor, Would You Like to Create Your Own Direct Primary Care Practice? The Bottom Line Direct Care is not a miracle or a movement requiring belief. It is a rearrangement of incentives. When a physician is paid to keep you well rather than to process encounters, prevention beats crisis management, patients come in early instead of waiting, and the adversarial triangle between patient, physician, and insurer collapses into an actual relationship. For integrative and functional medicine — where the work is slow, iterative, and deeply personal — that rearrangement is not a nicety. It is what makes the medicine possible at all. If you are managing a complex condition and want to discuss whether this approach fits your situation, you can learn more or reach out at directintegrativecare.com. About Dr. Kim Yoon Hang "John" Kim, MD, MPH, is board-certified in Preventive Medicine and is an Integrative & Functional Medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona's Andrew Weil Center for Integrative Medicine and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and over 20 published articles, and has helped establish integrative medicine programs at institutions nationwide. Yoon Hang Kim, MD, MPH Integrative & Functional Medicine Physician Based in San Antonio, Texas · Virtual practice serving TX, IA, IL, MO, FL, and GA www.yoonhangkim.com | www.directintegrativecare.com Related Reading Endorphins: Biochemistry, Bioregulation, and Clinical Levers Navigating Supplement and Medication Sequencing in ME/CFS–MCAS Overlap 15 Teaching Points from the LDN Support Group Pop-Up Live Pharmacogenomics and Naltrexone: Can Your Genes Predict How You Respond? Why Autoimmune Disease Affects Women More Often Than Men #DirectPrimaryCare #DirectCare #IntegrativeMedicine #FunctionalMedicine #DPC #MembershipMedicine #SanAntonio #RootCauseMedicine #HSA #PhysicianBurnout #PatientCentered References Kaiser Family Foundation. 2025 Employer Health Benefits Survey. October 2025. https://www.kff.org/health-costs/2025-employer-health-benefits-survey/ Mercer. Employers Prepare for the Highest Health Benefit Cost Increase in 15 Years. September 2025. https://www.mercer.com/en-us/insights/us-health-news/employers-prepare-for-the-highest-health-benefit-cost-increase-in-15-years/ Gunja MZ, et al. The Causes and Impacts of Burnout Among Primary Care Physicians in 10 Countries. Commonwealth Fund, November 2025. https://www.commonwealthfund.org/publications/surveys/2025/nov/causes-impacts-burnout-primary-care-physicians-10-countries Porter J, Boyd C, Skandari MR, Laiteerapong N. Revisiting the time needed to provide adult primary care. J Gen Intern Med. 2023;38(1):147–155. doi:10.1007/s11606-022-07707-x. PMID: 35776372. Sinsky CA, Shanafelt TD, Dyrbye LN, Sabety AH, Carlasare LE, West CP. Health care expenditures attributable to primary care physician overall and burnout-related turnover: a cross-sectional analysis. Mayo Clin Proc. 2022;97(4):693–702. doi:10.1016/j.mayocp.2021.09.013. PMID: 35339279. Society of Actuaries / Milliman. Direct Primary Care: Evaluating a New Model of Delivery and Financing. May 2020. https://www.milliman.com/en/insight/what-our-study-says-about-direct-primary-care American Academy of Family Physicians. Answers to six common questions about direct primary care (citing the AAFP 2024 DPC Data Brief; average panel size 402). https://www.aafp.org/pubs/fpm/blogs/inpractice/entry/dpc-faqs.html One Big Beautiful Bill Act (H.R. 1). Signed July 4, 2025; HSA/DPC provisions effective January 1, 2026. See IRS Revenue Procedure 2026-24 and IRS Notice 2026-05. DPC Frontier. Opting Out of Medicare. https://www.dpcfrontier.com/opting-out-of-medicare Direct Primary Care Coalition. https://www.dpcare.org/ Direct Primary Care Alliance. https://www.dpcalliance.org/ Direct Specialty Care Alliance. https://dscalliance.org/ Free Market Medical Association. https://fmma.org/

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com Disclaimer: This blog post is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Low dose naltrexone (LDN) is used off-label for essentially all of the conditions discussed below; it is not FDA-approved for any of them. Always consult with a qualified clinician before starting, adjusting, or discontinuing any medication. Individual responses to LDN vary considerably. One of the questions I hear most often in my practice is this: If I develop significant side effects from LDN, should I power through them? My answer depends on the level of side effect — but when they are significant, the answer is almost always no. When Rapid Titration Outpaces the Body's Capacity I recently worked with a patient who increased their dose very rapidly. The initial steps went smoothly — from 1 microgram (0.001 mg) to 5 micrograms (0.005 mg), no problems. But from there, the jumps to 10 and then 20 micrograms triggered significant side effects. This is not an unusual pattern. Individuals who are doing well at the lowest doses can be tempted — or advised — to move quickly toward higher targets. But the pace of titration matters at least as much as the destination dose. Side effects during a dose increase are not a signal to push harder; they are a signal that the increase was either too fast or too large for that person's system at that time. This pattern — tolerating very low doses well but encountering problems with larger jumps — is one of the most common and most avoidable sources of difficulty in LDN therapy.[1],[2] Why "Powering Through" Can Be the Wrong Move There is a common assumption, sometimes reinforced in online communities, that LDN side effects are just something to tolerate until the body adjusts. In some cases that is true — mild, transient vivid dreams or brief sleep disruption during the first one to two weeks often resolve without any change in dose.[3],[4] But when side effects are significant — meaning they interfere meaningfully with sleep, function, energy, mood, or quality of life — my standard recommendation is straightforward: stop the LDN. This is not a failure of the medication or of the patient. It is the safest way to reset the system, gather information, and plan a more careful approach. The Recovery Period: What It Involves and How Long It Takes Once LDN has been stopped, the next step is allowing the body enough time to recover before any restart is considered. In my clinical experience, this recovery window can range considerably depending on the individual: 3 to 7 days for mild-to-moderate reactions in otherwise non-sensitive individuals 7 to 14 days for more pronounced symptoms or moderately sensitive individuals 14 to 30 days for those with significant sensitivity syndromes, such as MCAS, ME/CFS, or conditions involving heightened nervous system reactivity The rationale for this recovery period involves several overlapping systems. The traditional proposed mechanism of LDN centers on a brief, partial blockade of opioid receptors followed by a compensatory upregulation of endogenous opioid production and receptor density — what some refer to as the "endorphin rebound."[5],[6] If a patient experiences significant adverse effects, the theory suggests that the opioid receptor system and related endorphin signaling need time to re-equilibrate before naltrexone is reintroduced. Editor's note on the endorphin rebound hypothesis: The concept that LDN's primary benefit derives from endorphin upregulation is widely cited, but the evidence is more nuanced than the popular narrative suggests. A 2021 study by Metz, Daimon, and Hentges in eNeuro examined whether LDN alters the activity of proopiomelanocortin (POMC) neurons in mice — the hypothalamic neurons responsible for producing β-endorphin — and found no evidence that LDN changed opioid receptor sensitivity on POMC neurons, Pomc mRNA production, or plasma β-endorphin levels.[7] The authors concluded that LDN's reported benefits appear to be independent of the POMC/β-endorphin pathway. This does not invalidate the clinical observation that a recovery period is needed after significant side effects. It does suggest that what is "recovering" may involve broader opioid receptor re-equilibration, glial and neuroinflammatory system resettling, or nervous system recalibration rather than a simple endorphin deficit. Animal data clearly show that naltrexone administration leads to robust mu-opioid receptor upregulation — increasing receptor density by as much as 93% — with gradual normalization over subsequent days.[8],[9] That receptor-level normalization, combined with the nervous system's broader adaptive response, likely contributes to the clinically observed need for a washout period before safe reinitiation. The honest summary: the recovery period is clinically real and well-supported by practice experience. The precise mechanism driving it is less settled than many accounts imply, and attributing it solely to "endorphin deficiency" oversimplifies the biology. Restarting Requires Expert Guidance After the recovery period, the patient should not simply resume at the same dose that caused difficulty. The appropriate restart strategy depends on the full clinical picture — what the side effect was, how severe it was, how sensitive the person's system has shown itself to be, and what underlying conditions are in play. In many cases, restarting at a substantially lower dose and titrating more slowly is sufficient. For highly sensitive individuals, the restart dose may need to be in the low microgram range — sometimes even lower — before any upward movement is attempted.[10] The specific dosing tiers (microgram, nanogram, and in rare cases picogram) and the pharmacologic rationale for them are discussed in greater detail in the companion post LDN Primer Follow-Up: What to Do When LDN Causes Side Effects. This is precisely the kind of decision that should be made in partnership with a clinician experienced in LDN titration across the full dosing spectrum — not self-directed based on another person's experience or a standardized protocol. The Value of Expert Guidance in LDN Therapy LDN is a powerful tool, but it is not a simple one. The difference between a productive LDN experience and a difficult one often comes down to the titration strategy — how quickly the dose is advanced, how side effects are interpreted, whether the clinician has the experience to recognize when a pause, a step back, or a reformulation is needed. If you have had to stop LDN because of side effects, that is not the end of the road. But the path forward should be individualized, informed by your specific response pattern, and guided by someone who understands the pharmacology and clinical nuance of this medication. Summary Step Action Side effects emerge Assess severity. Mild and transient symptoms (vivid dreams, brief sleep disruption) may resolve on their own within 1–2 weeks. Significant side effects Stop LDN. Do not attempt to push through symptoms that meaningfully impair function, sleep, or quality of life. Recovery period Allow the system to settle — typically 3 to 30 days depending on individual sensitivity and the severity of the reaction. Restart planning Work with an LDN-experienced clinician to determine the appropriate restart dose and titration schedule. The restart dose may be substantially lower than the dose that caused difficulty. #LDN #LowDoseNaltrexone #LDNSideEffects #IntegrativeMedicine #FunctionalMedicine #LDNTitration #ChronicPain #MCAS #LDNSupportGroup #EvidenceBasedMedicine References Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250 Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820–828. doi:10.1111/j.1572-0241.2007.01045.x. PMID: 17222320 (Sleep disturbance was the single most common side effect.) Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734. PMID: 23359310 Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMID: 30248938 Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. (Proposed mechanism includes temporary receptor blockade followed by compensatory endorphin upregulation and increased receptor density.) PMID: 24526250 Kim YH. Endorphins: Biochemistry, Bioregulation, and Clinical Levers. Integrative Functional Medicine and LDN Community (ifmsynergy.com). Published July 16, 2026. https://www.ifmsynergy.com/endorphins-biochemistry-bioregulation-and-clinical-levers/ Metz MJ, Daimon CM, Hentges ST. Reported benefits of low-dose naltrexone appear to be independent of the endogenous opioid system involving proopiomelanocortin neurons and β-endorphin. eNeuro. 2021;8(3):ENEURO.0087-21.2021. doi:10.1523/ENEURO.0087-21.2021. PMID: 34031099 Lesscher HMB, Bailey A, Burbach JP, van Ree JM, Kitchen I, Gerrits MAFM. Receptor-selective changes in μ-, δ- and κ-opioid receptors after chronic naltrexone treatment in mice. Eur J Neurosci. 2003;17(5):1006–1012. doi:10.1046/j.1460-9568.2003.02538.x. PMID: 12653976 Tempel A, Gardner EL, Zukin RS. Opioid antagonist modulation: naltrexone-induced receptor upregulation. Eur J Pharmacol. 1984;106(1):101–106. doi:10.1016/0014-2999(84)90683-9. PMID: 6152212 (Naltrexone treatment increased opioid receptor density by up to 93%, normalizing over subsequent days.) Kim YH. LDN Primer Follow-Up: What to Do When LDN Causes Side Effects. Integrative Functional Medicine and LDN Community (ifmsynergy.com). Published July 14, 2026. https://www.ifmsynergy.com/ldn-primer-follow-up-what-to-do-when-ldn-causes-side-effects/ Related Reading 15 Teaching Points from the LDN Support Group Pop-Up Live — An Evidence-Referenced Review Endorphins: Biochemistry, Bioregulation, and Clinical Levers Pharmacogenomics and Naltrexone: Can Your Genes Predict How You Respond? About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience spanning preventive medicine, integrative and functional medicine, medical acupuncture, and integrative holistic medicine. A fellowship-trained graduate of the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil, Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of three books and more than 20 published articles in integrative medicine. Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com

Beyond the Blue Pill: A Functional Medicine Approach to Erectile Dysfunction Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Medical Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Erectile dysfunction can be a sign of serious underlying health conditions, including cardiovascular disease. Always consult a qualified healthcare provider before starting any new treatment or supplement regimen. Nothing in this article should replace professional medical evaluation and management. Introduction: The Canary in the Coal Mine Erectile dysfunction (ED) affects an estimated 30 million men in the United States and over 150 million worldwide. Its prevalence rises sharply after age 40. In conventional medicine, the conversation often begins and ends with a prescription for a phosphodiesterase-5 (PDE-5) inhibitor—sildenafil, tadalafil, or one of their pharmacological cousins. These medications are effective for many men, but they treat the symptom without asking a more fundamental question: why is this happening in the first place? In functional and integrative medicine, we view ED not as an isolated mechanical failure but as a systemic signal—a canary in the coal mine that reflects deeper disruptions in vascular health, hormonal balance, metabolic function, gut integrity, and even psychological resilience. An erection, after all, is one of the most vascular-dependent events in human physiology. When the endothelial lining of blood vessels becomes compromised, the penile vasculature is often among the first casualties—frequently presenting years before a cardiovascular event like a heart attack or stroke. This article explores the root causes of ED through a functional medicine lens and outlines a comprehensive, evidence-informed approach to restoring sexual health by treating the whole person. The Nitric Oxide Connection: Where It All Begins At the molecular level, erectile function depends on nitric oxide (NO). Sexual stimulation triggers the release of NO from nerve endings and endothelial cells in the penile vasculature. NO activates soluble guanylyl cyclase, which increases cyclic guanosine monophosphate (cGMP), ultimately relaxing the smooth muscle of the corpus cavernosum and allowing blood engorgement. PDE-5 inhibitors work downstream in this cascade by preventing the breakdown of cGMP—but they cannot generate what isn't being produced in the first place. When the endothelium is damaged by chronic inflammation, oxidative stress, insulin resistance, or hyperlipidemia, NO bioavailability drops. This endothelial dysfunction is the shared pathophysiological highway connecting ED to cardiovascular disease, hypertension, diabetes, and metabolic syndrome. Research published in the Journal of Clinical Hypertension has confirmed that impaired NO signaling is the primary biochemical mechanism underlying organic ED. This insight is transformative for clinical practice. Rather than simply prescribing a PDE-5 inhibitor and moving on, a functional medicine approach asks: what is damaging the endothelium? What is suppressing NO production? And what can we do to restore it? Hormonal Terrain: More Than Just Testosterone Testosterone plays a well-established role in libido, arousal, and the maintenance of penile tissue health. Androgen deficiency is associated with penile smooth muscle atrophy, increased extracellular matrix deposition, and reduced expression of PDE-5 itself—which may explain why some hypogonadal men respond poorly to PDE-5 inhibitors alone. Testosterone replacement therapy has been shown to improve both erectile function scores and libido in hypogonadal men, and combination therapy with PDE-5 inhibitors may benefit those who fail monotherapy. However, testosterone is only one piece of a complex hormonal puzzle. A thorough functional medicine evaluation also considers: Estrogen balance: Elevated estradiol (often driven by aromatase activity in visceral adipose tissue) can suppress gonadotropin signaling and directly impair erectile function. Thyroid function: Both overt and subclinical hypothyroidism are associated with ED, partly through effects on vascular reactivity and partly through sexual desire. Cortisol and the HPA axis: Chronic stress and HPA axis dysregulation suppress gonadotropin-releasing hormone (GnRH) pulsatility, which in turn reduces luteinizing hormone (LH) and testosterone production. Cortisol also directly impairs NO-mediated vasodilation. Prolactin: Hyperprolactinemia, whether from medications (e.g., SSRIs, antipsychotics) or pituitary pathology, is a recognized but frequently overlooked cause of ED. DHEA-S and pregnenolone: These upstream adrenal precursors decline with age and chronic stress and may influence sexual function through downstream hormonal effects. Comprehensive hormonal testing—including total and free testosterone, SHBG, estradiol, DHEA-S, cortisol (ideally via a diurnal curve or DUTCH testing), thyroid panel, and prolactin—provides the detailed map needed to address hormonal contributors to ED. Metabolic and Vascular Health: The Foundation Metabolic syndrome—the clustering of central obesity, dyslipidemia, hyperglycemia, and hypertension—is one of the strongest predictive constellations for ED. Insulin resistance drives endothelial dysfunction through multiple mechanisms: increased oxidative stress, elevated advanced glycation end-products (AGEs), chronic low-grade inflammation, and impaired NO synthase activity. In men with diabetes, ED prevalence may exceed 50%, and it often appears a decade or more before overt cardiovascular events. A functional medicine approach to the metabolic root causes of ED includes: Dietary optimization: A Mediterranean-style dietary pattern, rich in polyphenols, omega-3 fatty acids, fiber, and nitrate-containing vegetables (beets, arugula, spinach), has been shown in clinical studies to improve erectile function in men with metabolic syndrome. Dietary nitrates are converted to NO via the enterosalivary nitrate-nitrite-NO pathway, providing an additional source of NO independent of endothelial synthase. Blood sugar regulation: Addressing insulin resistance through dietary carbohydrate modification, time-restricted eating, and targeted supplementation (berberine, chromium, alpha-lipoic acid) can improve endothelial function. Lipid management: Oxidized LDL is directly toxic to endothelial cells. Addressing lipid oxidation through anti-inflammatory nutrition and targeted antioxidants may protect the penile vasculature. Exercise: Regular aerobic and resistance exercise improves endothelial function, increases NO production, enhances insulin sensitivity, and supports testosterone production. Compound resistance training, in particular, has been associated with acute and chronic improvements in androgen levels. Weight management deserves special emphasis. Visceral adiposity increases aromatase activity (converting testosterone to estradiol), drives systemic inflammation, and contributes to insulin resistance—all of which converge on erectile dysfunction. The Gut-Vascular Axis: An Emerging Frontier One of the most compelling areas of emerging research in functional medicine connects gut health to erectile function through the gut-vascular axis. Studies comparing the gut microbiota of men with ED to healthy controls have revealed significant differences in microbial composition, including higher abundances of Bacteroides, Fusobacterium, and Escherichia-Shigella and lower abundances of Bifidobacterium in ED clients. Several mechanisms link gut dysbiosis to ED: TMAO production: Certain gut bacteria convert dietary choline, carnitine, and betaine into trimethylamine (TMA), which the liver oxidizes to trimethylamine N-oxide (TMAO). Elevated TMAO levels promote atherosclerotic plaque formation, vascular inflammation, and endothelial damage—all of which impair penile blood flow. Lipopolysaccharide (LPS) translocation: Gut barrier dysfunction (increased intestinal permeability) allows bacterial endotoxins like LPS to enter the systemic circulation, triggering NF-κB-mediated inflammatory cascades that damage vascular endothelium. Inflammatory cytokine signaling: Dysbiosis-driven elevations in IL-1β and IL-6 have been negatively correlated with beneficial bacterial populations and positively correlated with ED severity. Hormonal modulation: The gut-testes axis influences testosterone metabolism and the estrobolome (the collection of gut bacteria capable of metabolizing estrogens), potentially affecting androgen-estrogen balance. Addressing gut health in ED clients may involve comprehensive stool analysis, targeted antimicrobial or antifungal protocols for dysbiosis or overgrowth, prebiotic and probiotic support (particularly Bifidobacterium species), gut barrier restoration (glutamine, zinc carnosine, immunoglobulins), and dietary modification to reduce TMAO-generating substrates. Nitric Oxide Support: Nutraceutical Strategies Given the central role of NO in erectile physiology, targeted nutraceutical support aimed at restoring NO bioavailability represents a key pillar of the functional medicine approach. The evidence base, while still growing, supports several promising interventions: L-Citrulline: Unlike oral L-arginine, which undergoes extensive first-pass hepatic metabolism, L-citrulline bypasses the liver and is converted to L-arginine in the kidneys, raising systemic arginine levels more effectively and sustainably. A pilot trial of men with mild ED demonstrated that 1.5 g/day of L-citrulline for one month improved erection hardness scores in 50% of participants compared to 8.3% on placebo. Doses of 3–6 g/day are commonly used in clinical practice and are generally well tolerated. A randomized clinical trial is currently underway comparing L-citrulline 1,500 mg/day, tadalafil 5 mg/day, and their combination. L-Arginine: A multicenter, double-blind, randomized, placebo-controlled trial found that high-dose L-arginine (6 g/day) for three months significantly improved erectile function scores and cavernous artery peak systolic flow velocity in men with vasculogenic ED—particularly those with mild-to-moderate disease. A meta-analysis of ten RCTs has confirmed these benefits across varying dosages and durations. Pycnogenol (French Maritime Pine Bark Extract): When combined with L-arginine, pycnogenol has shown synergistic effects on erectile function, likely through its role as an endothelial NO synthase (eNOS) activator and antioxidant. Beetroot juice and dietary nitrates: Concentrated beet juice provides inorganic nitrate that oral bacteria convert to nitrite and subsequently to NO via the non-enzymatic pathway, supporting vasodilation independently of eNOS function. Trans-resveratrol: A randomized, double-blind, placebo-controlled crossover study found that oral L-citrulline combined with trans-resveratrol improved erectile function in men already using PDE-5 inhibitors, suggesting additive mechanisms. Homocysteine, Methylation, and the B-Vitamin Connection An often-overlooked contributor to erectile dysfunction is hyperhomocysteinemia—elevated levels of the amino acid homocysteine in the blood. Animal research has demonstrated that elevated homocysteine impairs erectile function by directly reducing endothelial nitric oxide synthase (eNOS) activity and increasing oxidative stress in the cavernous tissue. Importantly, supplementation with B vitamins (particularly B6, B12, and folate) has been shown to mitigate these effects. In functional medicine practice, assessing homocysteine levels, methylation status (including MTHFR polymorphisms), and B-vitamin adequacy is a standard part of the workup for ED. Targeted methylation support—using methylfolate, methylcobalamin, and pyridoxal-5-phosphate—may address this upstream vascular risk factor. Psychological Health, Sleep, and Stress No functional medicine discussion of ED is complete without addressing the psychological and lifestyle dimensions. Performance anxiety, relationship conflict, depression, and unresolved trauma can all drive or perpetuate erectile difficulties, often creating a vicious cycle in which a single episode of difficulty generates anticipatory anxiety that ensures recurrence. Sleep quality and duration are frequently underappreciated. Testosterone production follows a circadian rhythm and is closely tied to REM sleep. Sleep apnea, in particular, is strongly associated with both ED and low testosterone, and CPAP therapy has been shown to improve sexual function in some men. A sleep evaluation—ideally including home sleep testing when obstructive sleep apnea is suspected—should be part of any comprehensive ED assessment. Chronic stress, through sustained HPA axis activation, depletes DHEA and testosterone while simultaneously elevating cortisol, which impairs NO-mediated vasodilation and reduces libido. Stress-management interventions—including mindfulness-based stress reduction, cognitive behavioral therapy, breathwork, and adaptogenic herbs (ashwagandha, rhodiola)—can play a meaningful therapeutic role. Medication-Induced ED: A Functional Medicine Red Flag A thorough functional medicine evaluation always includes a careful medication review. Many commonly prescribed drugs contribute to or cause ED, including: Antihypertensives: Thiazide diuretics and older beta-blockers (e.g., atenolol, metoprolol) are well-known offenders. Newer beta-blockers (nebivolol) and ARBs tend to be more sexually neutral. SSRIs and SNRIs: Serotonergic antidepressants cause sexual dysfunction—including ED, delayed ejaculation, and anorgasmia—in up to 70% of users. Statins: While the data is mixed, some men report sexual side effects on HMG-CoA reductase inhibitors, possibly through effects on cholesterol-dependent hormone synthesis. 5-alpha reductase inhibitors: Finasteride and dutasteride (used for BPH and hair loss) can cause persistent sexual dysfunction in a subset of men. Opioids: Chronic opioid use suppresses the hypothalamic-pituitary-gonadal axis, leading to hypogonadism and ED. In functional and integrative medicine, we explore whether root-cause treatment of the conditions these medications were prescribed for might allow dose reduction or discontinuation—always in collaboration with the prescribing clinician. Putting It All Together: The Functional Medicine Workup A comprehensive functional medicine evaluation for ED integrates the following components: Detailed history: Onset pattern (sudden vs. gradual), nocturnal/morning erections, situational versus global dysfunction, psychosocial stressors, relationship dynamics, medication and supplement review, sleep quality, exercise habits, and dietary patterns. Advanced laboratory assessment: Comprehensive metabolic panel, fasting insulin, HbA1c, lipid panel with particle size, high-sensitivity CRP, homocysteine, complete thyroid panel (TSH, free T3, free T4, thyroid antibodies), total and free testosterone, SHBG, estradiol, DHEA-S, prolactin, cortisol (AM or diurnal), vitamin D, B12, folate, RBC magnesium, and ferritin. Specialized testing as indicated: DUTCH hormone testing (for detailed androgen and cortisol metabolite analysis), comprehensive stool analysis (for gut microbiome and barrier assessment), organic acids testing, and pharmacogenomic testing (particularly relevant when considering medication adjustments). Cardiovascular assessment: Given that ED may precede cardiovascular events by 3–5 years, appropriate cardiovascular screening (coronary artery calcium score, carotid intima-media thickness, or advanced lipid testing) should be considered, especially in men over 40 presenting with new-onset ED. Conclusion: Treating the Man, Not Just the Erection Erectile dysfunction is far more than a bedroom inconvenience. It is a systemic health signal that, when properly interpreted, can reveal reversible root causes spanning vascular damage, hormonal imbalance, metabolic dysfunction, gut dysbiosis, nutritional deficiency, medication side effects, and psychological distress. PDE-5 inhibitors have their place—they are effective, well-studied, and sometimes necessary—but they are a symptom-management tool, not a root-cause solution. Functional and integrative medicine offers men a different path: a thorough investigation of the why behind the dysfunction, followed by a personalized, multimodal treatment plan that addresses the underlying biology. In doing so, we often improve not just erectile function but overall cardiovascular risk, metabolic health, energy, mood, and quality of life. If you are experiencing erectile dysfunction and want to explore a root-cause approach, consider working with a functional medicine clinician who can provide the comprehensive evaluation and individualized treatment plan that this condition deserves. To learn more about a functional and integrative medicine approach to men's health, visit www.directintegrativecare.com. ________________________________________ About Dr. Kim Dr. Yoon Hang “John” Kim is board-certified in Preventive Medicine and certified in Integrative and Holistic Medicine, Medical Acupuncture (UCLA), and Functional Medicine (IFM Scholar). With over 20 years of clinical experience, he completed his fellowship training under Dr. Andrew Weil at the University of Arizona Center for Integrative Medicine. He specializes in low dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of three books and more than 20 peer-reviewed publications. Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com References Burnett AL. The role of nitric oxide in erectile dysfunction: implications for medical therapy. J Clin Hypertens (Greenwich). 2006;8(12 Suppl 4):53-62. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61. Cormio L, De Siati M, Lorusso F, et al. Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology. 2011;77(1):119-122. Menafra D, de Angelis C, Garifalos F, et al. Long-term high-dose L-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. J Endocrinol Invest. 2022;45(5):941-961. Zhao M, Yuan L, Liang S, et al. Gut microbiota composition may be an indicator of erectile dysfunction. MicrobiologyOpen. 2024;13(1):e1397. Liu S, Li C, Qin Y, et al. Correlation between gut microbiota diversity and psychogenic erectile dysfunction. Transl Androl Urol. 2021;10(12):4412-4421. Jiang W, Xiong L, Li W, et al. Hyperhomocysteinaemia in rats is associated with erectile dysfunction by impairing endothelial nitric oxide synthase activity. Sci Rep. 2016;6:26647. Rizk PJ, Kohn TP, Pastuszak AW, Khera M. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017;27(6):511-515. Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18(4):405-410. 10. Wang X, Xie Z. Trimethylamine N-oxide and erectile dysfunction: a review of the gut-vascular axis. Front Endocrinol (Lausanne). 2022;13:1003891. 11. Schwedhelm E, Maas R, Freese R, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. 2008;65(1):51-59. 12. Colao A, Pivonello R, et al. Integrative natural approaches for age-related testosterone decline: a synergistic framework combining exercise, nutrition, and bioactive compounds. Nutrients. 2025;17(4):XXX. 13. Osman A, et al. Comparison of the gut microbiome composition between men with erectile dysfunction and a matched cohort: a pilot study. Andrology. 2024;12(1):45-55. 14. Fortney L. Erectile dysfunction. In: Rakel D, ed. Integrative Medicine. 4th ed. Elsevier; 2018:623-629.e2.

www.directintegrativecare.com The Layered Approach to Mast Cell Activation Syndrome: Integrating Dr. Afrin's Framework with Functional Medicine Therapeutics LDN, Ketotifen, Methylene Blue, Quercetin, and Luteolin in a Stepwise Clinical Model Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Medical Disclaimer This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Mast Cell Activation Syndrome (MCAS) management must be individualized under the guidance of a qualified healthcare provider. Do not start, stop, or modify any treatment based on this information alone. Always consult your physician before making changes to your care plan. Introduction: Why a Layered Approach Is Necessary Mast Cell Activation Syndrome (MCAS) is a condition in which mast cells—normally protective immune sentinels stationed throughout connective tissue, mucosal surfaces, and perivascular spaces—become chronically dysregulated, releasing a disproportionate cascade of mediators including histamine, prostaglandins, leukotrienes, tryptase, and cytokines. The clinical result is a multi-system inflammatory syndrome that can mimic dozens of other conditions, presenting with symptoms spanning the gastrointestinal, dermatologic, cardiovascular, neuropsychiatric, and musculoskeletal systems simultaneously. What makes MCAS particularly challenging is not simply the breadth of symptoms but the heterogeneity of individual mediator profiles. No two clients present identically. Dr. Lawrence Afrin, a hematologist-oncologist widely regarded as the foremost clinical authority on mast cell disease, has remarked in interviews that he did not encounter a case bearing reasonable similarity to any previous one until he had seen roughly seventy MCAS clients—an anecdotal observation rather than a published statistic, but one that captures the extraordinary biological variability at the core of this condition. This heterogeneity demands a layered, stepwise treatment strategy—one that builds sequentially, adds one intervention at a time, and allows for careful clinical observation at each stage. Dr. Afrin's guiding principles of patience, persistence, and a methodical approach remain the gold standard for MCAS management. The functional and integrative medicine framework extends this further by incorporating immunomodulatory agents, natural mast cell stabilizers, and mitochondrial support that address not only mediator blockade but root-cause drivers of mast cell dysfunction. This article presents a layered clinical model that integrates Dr. Afrin's foundational pharmacologic approach with the functional medicine toolkit I employ at www.directintegrativecare.com—specifically incorporating low-dose naltrexone (LDN), ketotifen, methylene blue (MB), quercetin, and luteolin. Cross-references to prior clinical reviews published on this topic are available at ifmsynergy.com/tag/mcas. Layer 1: The Afrin Foundation — H1 and H2 Antihistamines Every published treatment algorithm for MCAS begins with dual histamine receptor blockade. This is not optional—it is the pharmacologic floor upon which all subsequent layers are built. Histamine acts on four receptor subtypes (H1 through H4), but currently available therapeutics target only H1 and H2. By blocking both receptor classes simultaneously, clinicians achieve broader coverage of histamine-mediated symptoms including flushing, pruritus, urticaria, tachycardia, gastrointestinal distress, and headache. A point of mechanistic precision is warranted here, because a claim circulating widely in the integrative MCAS literature is stated backwards. It is often asserted that famotidine stabilizes mast cells because H2 receptors sit on the mast cell surface. Human mast cells do express H2 receptors—but H2 signaling on the mast cell raises intracellular cAMP and inhibits mediator release, functioning as a negative-feedback brake. Blocking that receptor does not stabilize the mast cell. The sound rationale for H2 blockade in MCAS is different and still compelling: H2 receptors are widely distributed on target tissues throughout the gastrointestinal tract, cardiovascular system, and elsewhere, so H2 antagonism blocks a large share of histamine's downstream effects that H1 blockade leaves untouched. A proton pump inhibitor does not substitute, because it suppresses acid production rather than blocking histamine at its receptor. Second-generation H1 antihistamines such as cetirizine or fexofenadine are preferred over first-generation agents (diphenhydramine, hydroxyzine) due to their superior side effect profiles and longer half-lives. MCAS clients frequently require doses at two to four times FDA-approved levels under medical supervision. These medications work prophylactically—once histamine-mediated symptoms appear, receptor binding has already occurred, and the therapeutic window has been missed. This foundational layer alone provides meaningful symptom reduction in most MCAS clients. Dr. Afrin has observed that a fortunate subset achieves satisfactory control with H1/H2 blockade alone. For the majority, however, this layer establishes a baseline from which additional agents are methodically introduced. Layer 2: Mast Cell Stabilization — Ketotifen and Cromolyn Sodium When antihistamines alone do not provide adequate control, the next logical escalation is the addition of agents that prevent mast cell degranulation itself—shifting the strategy from blocking released mediators to preventing their release in the first place. Ketotifen: Dual-Action Systemic Stabilizer Ketotifen occupies a unique pharmacologic niche as both a mast cell stabilizer and an H1 antihistamine. This dual mechanism makes it particularly valuable in MCAS management. Its stabilizing action involves inhibition of calcium influx across mast cell membranes, which reduces the release of histamine, tryptase, prostaglandins, and other mediators. Simultaneously, its H1 receptor antagonism provides an additional layer of histamine blockade beyond what cetirizine or fexofenadine provide alone. In functional medicine practice, ketotifen is frequently used as a bridge therapy—providing symptom control while deeper root causes such as gut dysbiosis, mold exposure, chronic infections, or heavy metal burden are being identified and addressed. It is available in the United States primarily through compounding pharmacies, as the oral formulation is not commercially marketed domestically. Common starting doses range from 0.5 to 1 mg at bedtime, with titration guided by clinical response and side effects (primarily initial sedation). Maximum therapeutic effect typically requires six to twelve weeks of consistent use—a timeline that reinforces Dr. Afrin's emphasis on patience in MCAS management. Cromolyn Sodium: The GI-Focused Stabilizer Cromolyn sodium remains the gold standard for GI-predominant MCAS presentations. Its negligible systemic absorption (less than one percent reaches the circulation) means it acts almost exclusively at the mucosal surface of the gastrointestinal tract—precisely where a high concentration of mast cells resides. This local action makes it particularly effective for abdominal pain, nausea, bloating, diarrhea, and food-related mast cell activation without introducing systemic side effects. Cromolyn requires slow introduction in sensitive MCAS clients, often beginning at one-quarter of an ampule and titrating upward over weeks. Full therapeutic benefit may take four to eight weeks to manifest. It is available as an oral solution (Gastrocrom) or can be compounded into capsules for clients sensitive to the liquid formulation's excipients. Layer 3: Immunomodulation — Low-Dose Naltrexone (LDN) The third layer introduces a mechanistic shift from mediator blockade and mast cell stabilization to upstream immunomodulation. Low-dose naltrexone represents one of the most compelling additions to the MCAS treatment algorithm, operating through pathways distinct from any antihistamine or stabilizer. At doses of 0.5 to 4.5 mg daily (typically administered at bedtime), LDN functions as a short-acting mu-opioid antagonist that transiently blocks opioid receptors. This paradoxical blockade triggers a compensatory upregulation of endogenous endorphins and enkephalins—peptides that do far more than modulate pain and mood. They bind to regulatory T cells, influencing T-lymphocyte and B-lymphocyte production and thereby recalibrating the adaptive immune response. The mechanisms by which LDN may benefit MCAS are multi-layered, though it should be said plainly that they are inferred from adjacent literature rather than demonstrated in MCAS clients directly. LDN antagonizes Toll-like receptor 4 (TLR4), a pattern recognition receptor whose activation drives NF-κB-mediated inflammatory cascades; TLR4 is expressed on mast cells and microglia alike, and its inhibition reduces production of pro-inflammatory cytokines including IL-6 and TNF-α while promoting anti-inflammatory mediators such as IL-10. LDN also modulates microglial activation, a mechanism with particular relevance for clients presenting with neuroinflammation, brain fog, and neuropsychiatric symptoms. A further proposed pathway is that T-cell microparticles activate mast cells and that LDN's reduction of excessive T-cell dysfunction disrupts this loop—this remains a hypothesis rather than an established mechanism, and Weinstock, who proposed it, has been explicit that the existence of opioid receptors on mast cells themselves is not clear. The clinical evidence base consists of case reports, small case series, and uncontrolled clinical audits rather than randomized controlled trials, and the figures deserve to be stated precisely rather than rounded upward. In the frequently cited 2018 BMJ Case Report by Weinstock and colleagues, a client with severe POTS and MCAS received ultra-low-dose naltrexone at 1 mg nightly; after six weeks this produced a 7% decrease in POTS severity scores and a 17% decrease in MCAS severity scores, with improvement in body pain, mood, memory, sleep, flushing, odor and food sensitivities, and paresthesia. Larger gains followed the subsequent addition of IVIg and rifaximin, so the composite response reported in that case cannot be attributed to naltrexone alone. A figure widely quoted as "LDN Research Trust data" is more accurately described as Dr. Leonard Weinstock's own unpublished clinical audit, presented in a video interview hosted by the Trust. In that series of 116 MCAS clients, 60% reported some improvement, 20% reported no effect, and 20% discontinued because of side effects—a discontinuation rate that is unsurprising given how frequently MCAS clients react to medications and excipients. Within the 70 clients who improved, the symptom-level numbers are small and should not be overstated: abdominal pain improved in 15, joint pain and fatigue in 11 each, muscle pain in 9, diarrhea in 6, constipation and restless legs in 5 each, and reduction in mast cell flares specifically in only 4. A 2025 clinical audit from University Hospitals of Leicester provides a second uncontrolled data point: 40 MCAS clients treated with LDN alone showed improvement in joint pain, fatigue, and gastrointestinal and skin symptoms, while 20 did not tolerate the medication. All clients in that cohort were already receiving antihistamines and mast cell stabilizers before LDN was added, which is consistent with the layered model described here—LDN was an addition to a foundation, not a replacement for it. In my clinical practice, LDN is positioned at Layer 3 because it addresses a fundamentally different axis of MCAS pathophysiology—immune dysregulation—rather than simply blocking mediators or stabilizing membranes. For a detailed mechanistic review, see my prior article: Why Low-Dose Naltrexone Calms Mast Cells. Layer 4: Natural Mast Cell Stabilizers — Quercetin and Luteolin The fourth layer incorporates natural flavonoids that provide mast cell stabilization through mechanisms complementary to pharmaceutical agents. Quercetin and luteolin are the two most extensively studied natural mast cell stabilizers and are widely used in integrative MCAS management. Quercetin Quercetin is a bioflavonoid found in onions, apples, berries, and green tea that inhibits the release of histamine, tryptase, and pro-inflammatory cytokines from mast cells. Its mechanism involves modulation of intracellular calcium signaling, inhibition of NF-κB activation, and suppression of protein kinase C pathways involved in mast cell degranulation. It also inhibits the release of prostaglandins and leukotrienes, addressing mediator pathways beyond histamine alone. The primary limitation of quercetin is poor oral bioavailability—absorption of standard formulations is low enough that the plasma concentrations achieved in humans fall well below those used in the cell culture experiments that demonstrate mast cell inhibition. This gap between in vitro potency and in vivo exposure is the central caveat for all flavonoid therapy. Liposomal or phytosome-complexed preparations improve absorption and are preferred in clinical practice. Typical dosing ranges from 500 to 1,000 mg daily, often combined with vitamin C, which is reported to support diamine oxidase activity and histamine metabolism—though the human evidence for that specific interaction is modest. While most mechanistic studies remain preclinical, the favorable safety profile and the broad anti-inflammatory, antioxidant, and mast cell stabilizing properties of quercetin make it a rational addition to the MCAS treatment stack, particularly for clients who are sensitive to pharmaceutical agents or prefer to minimize medication burden. Luteolin Luteolin, found in celery, chamomile, green peppers, and parsley, shares quercetin's mast cell stabilizing properties but offers distinct advantages, particularly for neuroinflammatory presentations. Research demonstrates that luteolin inhibits mast cell activation by suppressing intracellular calcium influx and blocking protein kinase C activation—the same signaling pathways through which the related flavonols act. It is worth noting that the published head-to-head comparison against cromolyn was conducted with quercetin, not luteolin; claims that luteolin specifically outperforms cromolyn are frequently repeated in the integrative literature but are extrapolated rather than directly demonstrated. What distinguishes luteolin from quercetin is its ability to cross the blood-brain barrier. This makes it uniquely valuable for MCAS clients suffering from neuroinflammation, brain fog, and cognitive dysfunction, as it can directly modulate mast cells residing in the central nervous system and reduce microglial activation. For a comprehensive review, see: Luteolin for MCAS: A Natural Mast Cell Stabilizer Worth Understanding. In practice, quercetin and luteolin are often used in combination, as their complementary mechanisms—quercetin's broader systemic anti-inflammatory profile and luteolin's CNS penetration—provide more comprehensive coverage than either agent alone. Liposomal formulations of both are preferred for bioavailability. Typical luteolin dosing ranges from 100 to 300 mg daily. Layer 5: Mitochondrial and Neuroimmune Support — Methylene Blue The fifth layer introduces methylene blue (MB), a re-emerging therapeutic agent that occupies a unique position in the MCAS toolkit by addressing the mitochondrial dimension of mast cell dysfunction—a mechanism that no conventional antihistamine, mast cell stabilizer, or immunomodulator directly targets. Mast cells are metabolically active cells that depend heavily on mitochondrial function for both mediator synthesis and degranulation signaling. When mitochondrial function is compromised—whether from oxidative stress, chronic infection, environmental toxin exposure, or genetic polymorphisms—mast cells become more reactive and less responsive to stabilizing interventions. This is the pathophysiologic rationale for incorporating mitochondrial support into the MCAS treatment algorithm. At the low oral doses used in integrative practice—generally in the range of 5 to 20 mg daily, or roughly 0.1 to 0.3 mg/kg, well below the milligram-per-kilogram dosing used acutely for methemoglobinemia—methylene blue acts as an alternative electron carrier in the mitochondrial electron transport chain. It shuttles electrons between Complex I and Complex III, bypassing dysfunctional segments and restoring ATP production while simultaneously reducing the generation of reactive oxygen species (ROS). This dual action—enhanced energy output with reduced oxidative stress—directly supports cellular resilience, including mast cell membrane stability. Beyond its mitochondrial effects, methylene blue inhibits the nitric oxide–cyclic GMP (NO-cGMP) pathway, which has direct relevance to MCAS. Excessive nitric oxide production is implicated in mast cell-mediated vasodilation, flushing, and the vasomotor instability seen in POTS-MCAS overlap presentations. By downregulating cGMP, methylene blue may reduce both inflammatory signaling and vascular symptoms. Additionally, MB has demonstrated neuroprotective properties—crossing the blood-brain barrier and reducing microglial-mediated neuroinflammation, making it complementary to luteolin in addressing neuropsychiatric MCAS manifestations. Methylene blue does carry important precautions. It is contraindicated with serotonergic medications (SSRIs, SNRIs, MAOIs) due to the risk of serotonin syndrome. G6PD deficiency must be ruled out prior to initiation. Clients should be informed that MB will turn urine blue-green—a harmless but sometimes alarming effect. For a full review, see: Low Dose Methylene Blue in Functional Medicine. Clinical Algorithm: Matching Layers to Client Phenotype The layered model is not rigidly sequential for every client. The clinical art lies in identifying the predominant phenotype and selecting the layers most relevant to each individual's presentation. The following table maps common MCAS phenotypes to recommended layer priorities: Client Phenotype Layer 1 Foundation Layer 2–3 Escalation Rationale GI-Predominant H1/H2 blockers + Cromolyn Ketotifen, LDN, DAO enzymes Cromolyn acts locally with <1% absorption; ketotifen adds systemic stabilization Skin / Respiratory H1/H2 blockers + Ketotifen Quercetin, Luteolin, Cromolyn nasal Dual H1 blockade + mast cell stabilization; flavonoids reduce mediator release Neuroinflammatory / Brain Fog H1/H2 blockers + LDN Luteolin, Methylene Blue LDN modulates TLR4/microglia; luteolin crosses BBB; MB supports mitochondria Vasomotor / POTS Overlap H1/H2 blockers + LDN Ketotifen, Methylene Blue LDN + MB address NO pathway and flushing; ketotifen for systemic stabilization Multi-System / Refractory H1/H2 + Ketotifen + LDN MB, Quercetin/Luteolin, Cromolyn Layered combination across all mediator pathways; consider biologics if refractory Table adapted from clinical algorithms published at ifmsynergy.com/tag/mcas. All interventions require individualization under clinical supervision. Guiding Principles: The Afrin Framework Applied Dr. Afrin's three principles—patience, persistence, and a methodical approach—are not merely philosophical aspirations; they are clinical necessities. MCAS is not a condition that yields to aggressive polypharmacy or rapid-fire therapeutic changes. Each layer should be introduced as a single variable, maintained for an adequate trial period (typically four to twelve weeks depending on the agent), and assessed for both benefit and adverse effects before the next layer is added. This methodical escalation serves multiple purposes. It allows clinicians to identify which specific agents are producing benefit (or causing reactions), avoids the confounding effects of simultaneous multi-agent introduction, and respects the exquisite sensitivity that many MCAS clients have to new substances—including the very medications intended to help them. Even beneficial agents like cromolyn sodium and ketotifen can initially worsen symptoms in hypersensitive individuals if introduced too rapidly. The layered model also acknowledges that MCAS management is not about achieving perfection. The realistic clinical goal, as Dr. Afrin has articulated, is to help clients feel significantly better than their pre-treatment baseline the majority of the time. This is an important expectation to set, as both clinicians and clients benefit from understanding that complete symptom resolution is rarely achievable—but substantial, meaningful improvement is well within reach for most clients who pursue methodical, layered treatment. Conclusion MCAS requires a treatment approach as complex and individualized as the condition itself. The layered model presented here—antihistamine foundation, mast cell stabilization, immunomodulation with LDN, natural flavonoid support with quercetin and luteolin, and mitochondrial optimization with methylene blue—represents a synthesis of Dr. Afrin's evidence-based pharmacologic framework with the root-cause-oriented perspective of functional medicine. No single agent addresses all dimensions of mast cell dysregulation. Histamine blockade alone does not prevent degranulation. Stabilizers alone do not modulate the upstream immune signaling that drives mast cell hyperreactivity. Immunomodulators alone do not correct the mitochondrial dysfunction that makes mast cells more vulnerable to activation in the first place. It is the layered integration of these distinct mechanisms—each building upon and complementing the others—that offers clients the most comprehensive path toward stabilization and improved quality of life. The evidence base for several of these agents continues to evolve. Clinicians and clients alike must hold the tension between biological plausibility and the current limitations of rigorous clinical trial data. What is clear is that MCAS is treatable, that most clients can achieve meaningful improvement, and that the methodical, layered approach remains the most reliable path to that outcome. References Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports. 2018;2018:bcr-2017-221405. doi:10.1136/bcr-2017-221405 Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, Panse J, Butterfield J, Afrin LB. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Archives of Pharmacology. 2016;389(7):671–694. doi:10.1007/s00210-016-1247-1 Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease—a guide to diagnosis and therapeutic options. Annals of Medicine. 2016;48(3):190–201. doi:10.3109/07853890.2016.1161231 Toljan K, Vrooman B. Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences. 2018;6(4):82. Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. Frontiers in Cellular Neuroscience. 2019;13:353. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL, Theoharides TC. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. British Journal of Pharmacology. 2005;145(7):934–944. doi:10.1038/sj.bjp.0706246 Theoharides TC. Luteolin as a therapeutic option for multiple sclerosis. Journal of Neuroinflammation. 2009;6:29. doi:10.1186/1742-2094-6-29 Xiong ZM, Choi JY, Wang K, et al. Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria. Aging Cell. 2016;15(2):279–290. doi:10.1111/acel.12434 [Cited for methylene blue's mitochondrial-antioxidant mechanism; this study examined progeria fibroblasts, not mast cells.] Myers B, et al. Use of low dose naltrexone and hydroxycarbamide for mast cell disorders (ISM, MCAS, HaT). Journal of Cancer Prevention & Current Research. 2025;16(5):134–135. [Mini review / clinical audit, University Hospitals of Leicester, UK.] Weinstock LB, Brook JB, Molderings GJ. Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: retrospective case series. Naunyn-Schmiedeberg's Archives of Pharmacology. 2022;395(11):1441–1447. doi:10.1007/s00210-022-02282-8 Lippert U, Artuc M, Grützkau A, Babina M, Guhl S, Haase I, et al. Human skin mast cells express H2 and H4, but not H3 receptors. Journal of Investigative Dermatology. 2004;123(1):116–123. doi:10.1111/j.0022-202X.2004.22721.x Cardet JC, Castells MC, Hamilton MJ. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Current Allergy and Asthma Reports. 2013;13(1):10–18. doi:10.1007/s11882-012-0326-8 Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, Theoharides TC. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One. 2012;7(3):e33805. doi:10.1371/journal.pone.0033805 Note on evidence quality: References above were individually verified against primary sources. Readers should note that the flavonoid data (quercetin, luteolin) derive predominantly from in vitro and preclinical models; the methylene blue mitochondrial literature is largely non-mast-cell; and the LDN evidence in MCAS consists of case reports, case series, and registry data rather than randomized controlled trials. No agent discussed in this article is FDA-approved for MCAS. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of clinical experience. A graduate of the University of Arizona Integrative Medicine Fellowship (Osher Fellow under Dr. Andrew Weil), he holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, along with UCLA medical acupuncture certification and IFM Scholar status. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of 3 books and over 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com Keywords: MCAS, Mast Cell Activation Syndrome, layered treatment, LDN, low-dose naltrexone, ketotifen, methylene blue, quercetin, luteolin, mast cell stabilizer, functional medicine, integrative medicine, Dr. Afrin, histamine, cromolyn sodium, neuroinflammation, POTS

Why Work With Dr. Yoon Hang Kim for LDN Therapy: The Membership Model Advantage for Complex Conditions Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician If you're living with a complex, multi-system condition — Mast Cell Activation Syndrome, POTS, autoimmune disease, fibromyalgia, chronic Lyme, CRPS, or a cancer diagnosis where you're looking for evidence-informed adjunctive support — you've probably already learned a hard truth: conventional care wasn't built for you. Fifteen-minute visits, rotating providers, and rigid dosing protocols don't leave much room for the kind of careful, iterative work that conditions like these actually require. Low Dose Naltrexone (LDN) is a perfect example of why this matters. It's not a drug you start once and forget. LDN modulates immune signaling, calms neuroinflammation, and supports endorphin regulation — but how it does that for you depends on your specific condition, your other medications, your genetics, and how your body responds over time. Getting LDN right isn't a single decision. It's a relationship. And the physician guiding that relationship matters enormously. Why Dr. Kim: A Career Built Around LDN and Complex Conditions Yoon Hang "John" Kim, MD, MPH, isn't a physician who added LDN to a general practice as an afterthought. His clinical career, research, and leadership roles have been centered on the intersection of integrative medicine and complex chronic illness for over two decades. Dr. Kim completed a residential fellowship as an Osher Fellow under Dr. Andrew Weil at the University of Arizona — the gold standard in integrative medicine training. He holds a Master of Public Health, completed the UCLA Medical Acupuncture Training Program, and is board-certified in both Preventive Medicine and Integrative & Holistic Medicine. He holds IFM Scholar status and has authored 3 books — including the LDN Primer and a clinical LDN textbook — along with more than 20 peer-reviewed articles. His leadership positions reflect the same focus. Dr. Kim served as Medical Director of the Integrative Oncology Program at Miami Cancer Institute and as Director of the University of Kansas Medical Center Integrative Medicine Program, in addition to leadership roles at WellMed/Optum. These weren't administrative titles; they were program-building roles that required designing integrative protocols for medically complex populations — exactly the kind of clinical thinking LDN demands. A Depth of LDN Expertise That Few Physicians Can Match What sets Dr. Kim apart from the growing number of practitioners who prescribe LDN is the breadth and depth of his work with the therapy across multiple clinical domains: Chronic pain and autoimmune conditions: Dr. Kim uses LDN extensively for clients managing Complex Regional Pain Syndrome (CRPS), fibromyalgia, multiple sclerosis, Crohn's disease, MCAS, POTS, ME/CFS, chronic Lyme, endometriosis, PANS/PANDAS, and a wide range of autoimmune disorders. These aren't conditions where a standard starting dose and a follow-up in three months will suffice — they require a physician who understands how LDN interacts with each of these disease processes individually. Ultra-Low Dose Naltrexone (ULDN): In a 2019 peer-reviewed paper, Dr. Kim explored the clinical use of ultra-low dose naltrexone — microgram-level dosing — for chronic pain. His research highlights how ULDN can work synergistically with pain relief pathways, including augmenting opioid medications while reducing tolerance and enhancing the effects of acupuncture. This level of pharmacologic nuance matters when your condition doesn't respond to conventional LDN dosing alone. Pharmacogenomics and individualized dosing: Dr. Kim incorporates pharmacogenomic considerations — including COMT polymorphisms and CYP enzyme variations — into LDN prescribing. This means your dosing strategy isn't based on population averages; it's informed by how your body actually metabolizes and responds to the medication. Integrative oncology: Dr. Kim applies LDN protocols as evidence-based adjunctive therapy in cancer care, drawing on his years leading integrative oncology programs. For clients navigating cancer treatment, this means access to a physician who understands how LDN fits alongside conventional oncology — not in place of it. The endorphin blockade and "feeling worse before better": One of the most common reasons clients abandon LDN prematurely is the paradoxical worsening that can occur as the body adjusts to the temporary endorphin blockade. Dr. Kim actively educates his clients on this mechanism, preparing them for what to expect so they don't mistake an expected adjustment phase for treatment failure. Community leadership: Dr. Kim leads the LDN Support Group, a community of over 9,000 members, and collaborates with organizations like the LDN Research Trust to advance research, education, and advocacy for the therapy. This means his clinical work is continually informed by real-world client experiences across a massive, diverse population of LDN users. Why LDN Demands More Than a One-Time Prescription Complex conditions rarely respond to a fixed dose. A client starting LDN for MCAS may need a dramatically different titration path than someone using it for POTS, pediatric IBD, or as part of an integrative oncology plan. Pharmacogenomic factors, herb-drug interactions, compounding pharmacy quality, and overlapping diagnoses all shape the right starting dose and the pace of adjustment. Without ongoing access to a physician who actually understands these nuances, clients are often left to guess — or to give up before finding their effective dose. This is especially true for LDN, where the "sweet spot" is highly individual. Dr. Kim has developed the Kim LDN Optimal Dose Questionnaire™ — a structured clinical tool designed to help identify each client's ideal dosing range — because he understands that the difference between LDN working and not working is often a matter of milligrams, timing, and patience guided by expertise. How the Membership Model Solves This This is exactly why Dr. Kim's practice, www.directintegrativecare.com, is structured as a membership-based direct care model rather than a traditional fee-for-visit practice. Instead of paying per appointment and hoping your questions fit into a rushed slot, membership gives you: Direct, ongoing access to Dr. Kim for dose adjustments as your body responds — not just at your next scheduled follow-up Continuity of care with one physician who knows your full history, rather than a rotating cast of providers Time for complexity — the kind of unhurried, root-cause conversations that MCAS, POTS, autoimmune disease, CRPS, and oncology support genuinely require A sustainable long-term relationship, including a Maintenance tier for clients who've stabilized and need ongoing prescription continuity without the intensity of active workup Because the practice is capped at a limited number of active clients, doesn't accept insurance, and operates via telemedicine across Texas, Georgia, Florida, Iowa, Illinois, and Missouri, Dr. Kim isn't incentivized to rush visits or churn through volume. The membership structure exists specifically so that clients with complicated, LDN-responsive conditions get the iterative attention this therapy actually demands. What Working With Dr. Kim Looks Like Every LDN relationship starts with a thorough review of your history, prior treatments, labs, and — where appropriate — pharmacogenomic data. From there, Dr. Kim builds a personalized titration plan around your specific condition, goals, and tolerance. Membership means you're never stuck waiting weeks to report a side effect, ask about a compounding pharmacy switch, discuss a ULDN trial, or adjust your dose after a flare. That responsiveness is often the difference between clients who find LDN transformative and clients who give up on it too early. For clients outside Dr. Kim's licensed states or international clients, educational consultations are available to help you understand LDN therapy and work more effectively with your local prescriber. Is This Approach Right for You? If you're managing a complex, chronic condition and have felt like LDN — or integrative medicine in general — deserves more time and attention than conventional care allows, a membership-based relationship may be the structure that finally lets this therapy work the way it's meant to. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of clinical experience. He completed a fellowship in Integrative Medicine under Dr. Andrew Weil at the University of Arizona and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. He has served as Medical Director of the Integrative Oncology Program at Miami Cancer Institute and Director of the University of Kansas Medical Center Integrative Medicine Program. Dr. Kim specializes in Low Dose Naltrexone therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold-related illness. He is the author of 3 books — including the LDN Primer and a clinical LDN textbook — and more than 20 peer-reviewed articles. He leads the LDN Support Group (9,000+ members) and collaborates with the LDN Research Trust. Professional site: www.yoonhangkim.com | Clinical practice: www.directintegrativecare.com